Datasets:

ChatDOC
/

OCRFlux-pubtabnet-cross

Dataset card Data Studio Files Files and versions Community

Split (1)

train · 9.06k rows

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.

image_name stringlengths 68 68	type stringclasses 2 values	gt_table stringlengths 116 12.6k	table_fragment_1 stringlengths 43 8.42k	table_fragment_2 stringlengths 39 8.21k
f15d7bdbfa3ca446a0fa6cfc6699259fd4d097502d0fee2780769dd1aa2789d2.png	simple	<table><tr><td></td><td></td><td>B2</td><td>HTK</td><td>Euro Collins </td></tr><tr><td>Osmolality (mosm/kg)</td><td></td><td>323</td><td>310</td><td>406</td></tr><tr><td>Ions (mmol/l)</td><td>Na<sup>+</sup></td><td>22</td><td>15</td><td>10</td></tr><tr><td></td><td>K<sup>+</sup></td><td>150</td><td>9</td><td>115</td></tr><tr><td></td><td>Mg<sup>++</sup></td><td>10</td><td>4</td><td></td></tr><tr><td></td><td>Cl<sup>-</sup></td><td>10</td><td>50</td><td>15</td></tr><tr><td></td><td>SO4<sup>-</sup></td><td>85</td><td></td><td></td></tr><tr><td>Buffers (mmol/l)</td><td>PO4<sup>---</sup></td><td>6</td><td></td><td></td></tr><tr><td></td><td>HPO4<sup>--</sup></td><td></td><td></td><td>43</td></tr><tr><td></td><td>H2PO4<sup>-</sup></td><td></td><td></td><td>15</td></tr><tr><td></td><td>HCO3<sup>-</sup></td><td></td><td></td><td>10</td></tr><tr><td></td><td>Histidin</td><td></td><td>198</td><td></td></tr><tr><td>Osmotics (mmol/l)</td><td>Glucose</td><td></td><td></td><td>198</td></tr><tr><td></td><td>Mannitol</td><td></td><td>30</td><td></td></tr><tr><td></td><td>Saccharin</td><td>40</td><td></td><td></td></tr><tr><td>Colloids (mmol/l)</td><td>PEG</td><td>25</td><td></td><td></td></tr></table>	<table><tr><td></td><td></td><td>B2</td><td>HTK</td><td>Euro Collins</td></tr><tr><td>Osmolality (mosm/kg)</td><td></td><td>323</td><td>310</td><td>406</td></tr><tr><td>Ions (mmol/l)</td><td>Na+</td><td>22</td><td>15</td><td>10</td></tr><tr><td></td><td>K+</td><td>150</td><td>9</td><td>115</td></tr><tr><td></td><td>Mg++</td><td>10</td><td>4</td><td></td></tr><tr><td></td><td>Cl-</td><td>10</td><td>50</td><td>15</td></tr><tr><td></td><td>SO4-</td><td>85</td><td></td><td></td></tr><tr><td>Buffers (mmol/l)</td><td>PO4---</td><td>6</td><td></td><td></td></tr><tr><td></td><td>HPO4--</td><td></td><td></td><td>43</td></tr><tr><td></td><td>H2PO4-</td><td></td><td></td><td>15</td></tr><tr><td></td><td>HCO3-</td><td></td><td></td><td>10</td></tr><tr><td></td><td>Histidin</td><td></td><td>198</td><td></td></tr></table>	<table><tr><td>Osmotics (mmol/l)</td><td>Glucose</td><td></td><td></td><td>198</td></tr><tr><td></td><td>Mannitol</td><td></td><td>30</td><td></td></tr><tr><td></td><td>Saccharin</td><td>40</td><td></td><td></td></tr><tr><td>Colloids (mmol/l)</td><td>PEG</td><td>25</td><td></td><td></td></tr></table>
71d91f59326e819e716b4352ecd8e0ea544d58dda15907399fab350f9f90132e.png	simple	<table><tr><td>Primer name</td><td>Oligonucleotide</td><td>Product length</td><td>Product name</td></tr><tr><td><i>crdPG-1</i></td><td>GTACTCGAGATTGTCGGCAGTCCAG</td><td>607</td><td><i>crdP</i></td></tr><tr><td><i>crdPG-2</i></td><td>AGCTCCTCGCCCTTGCTCACCATGAAATCAACTCCTCTGT</td><td></td><td></td></tr><tr><td>GFP-1</td><td>ACAGAGGAGTTGATTTCATGGTGAGCAAGGGCGAGGAGCT</td><td>746</td><td><i>GFP</i></td></tr><tr><td>GFP-2</td><td>CGCGGATCCTTACTTGTACAGCTCGTCCATG</td><td></td><td><i>crdP</i></td></tr><tr><td>crdP-1</td><td>TCACCAACACCAACTCTGGA</td><td></td><td></td></tr><tr><td>crdP-2</td><td>CATGAAATCAACTCCTCTGT</td><td>607</td><td><i>crdP</i></td></tr><tr><td>crdP142-1</td><td>ATCGTCAGATGCCTATTTGT</td><td>537</td><td><i>crdP</i></td></tr><tr><td>crdP108-1</td><td>AAATTAGTTAATGCAAT</td><td>503</td><td><i>crdP</i></td></tr><tr><td><i>crdP98-1</i></td><td>TTAATGCAATTTTTACTATGTT</td><td>493</td><td><i>crdP</i></td></tr><tr><td><i>crdP53</i>-1</td><td>CCATTTCAATACTGCGGGAGG</td><td>448</td><td><i>crdP</i></td></tr><tr><td><i>crdP13</i>-1</td><td>AGGAGTTGATTTCATGCTGTT</td><td>408</td><td><i>crdP</i></td></tr><tr><td><i>crdP1</i>-1</td><td>ATGCTGTTCCGCAATAAG</td><td>395</td><td><i>crdA</i></td></tr><tr><td><i>crdA395-2</i></td><td>TCGGTCCGCAGCAGCAAAG</td><td></td><td></td></tr><tr><td><i>q-crdA-1</i></td><td>CAAGGCATAAGCGAAGACATC</td><td>227</td><td><i>crdA</i></td></tr><tr><td><i>q-crdA-2</i></td><td>CTCCGTGTTTCAAGTGTGGTC</td><td></td><td></td></tr><tr><td><i>q-crdS-1</i></td><td>AACCTGACGATTGCGATTGGG</td><td>179</td><td><i>crdS</i></td></tr><tr><td><i>q-crdS-2</i></td><td>GTGTAGCACCAGAGCGTTTCG</td><td></td><td></td></tr><tr><td><i>q-crdC-1</i></td><td>GTTCGGTCAGGATGCTCAAC</td><td>248</td><td><i>crdC</i></td></tr><tr><td><i>q-crdC-2</i></td><td>GCCAAAGTTCGGAATCAATG</td><td></td><td></td></tr><tr><td><i>crdR-1</i></td><td>GCCAGATCTATGACCGAGAATAAGAAAAAGCCT</td><td>437</td><td><i>crdR</i></td></tr><tr><td><i>crdR-2</i></td><td>TTGAGCTCTTACTCGGCGTCGCCTTCG</td><td></td><td></td></tr><tr><td><i>NcrdR-1</i></td><td>ACACTCGAGATACACCCGGTCCCTACCAGCATT</td><td></td><td><i>crdR</i></td></tr><tr><td><i>NcrdR-2</i></td><td>TTTGAGCTCCTTGTCCTTCTTCAGAAGCGTGT</td><td>1302</td><td><i>crdR</i></td></tr><tr><td><i>q-crdR-1</i></td><td>TCGGAATGAGCCAGGAGAAGC</td><td>238</td><td><i>crdR</i></td></tr><tr><td><i>q-crdR-2</i></td><td>TCAGCCGAGGACAGAAAGTCG</td><td></td><td></td></tr><tr><td><i>crdRup-1</i></td><td>TCTGAGCTCTTCGGCGTTTCGGAATGGTTG</td><td>2533</td><td><i>CrdR</i></td></tr><tr><td><i>crdR</i>down-2</td><td>CAACACAAGCTTAACCGTCACCTGGCTCTTGGCA</td><td></td><td></td></tr><tr><td><i>crdR</i>checkGm-2</td><td>TTGGGCATACGGGAAGAAGT</td><td>558</td><td><i>Gm</i></td></tr><tr><td><i>crdR</i>checkGm-1</td><td>CGGCTGATGTTGGGAGTAGG</td><td>577</td><td></td></tr><tr><td>Rep-Kan-1</td><td>ACGCGTCGACCTTGCCAGCCCGTGGATAT</td><td>3266</td><td><i>Km</i></td></tr><tr><td>Rep-Kan-2</td><td>ACGCGTCGACTCTGTGATGGCTTCCATGTC</td><td></td><td></td></tr><tr><td>Gm-1</td><td>ATAGTTGTCGAGATATTCACTAGTCGTCAGGTGGCACTTTTCG</td><td>1302</td><td><i>Gm</i></td></tr><tr><td>Gm-2</td><td>CGCGGATCCGCTCTGCTGAAGCCAGTTAC</td><td></td><td></td></tr><tr><td>celAP1</td><td>ACCCGGTCTATCCCATGA</td><td></td><td></td></tr><tr><td>celAP-2</td><td>CATCCAGAAACTTTCCGT</td><td>441</td><td><i>celAP</i></td></tr><tr><td>relAP-1</td><td>CCAGATTTCTCAAGGGTC</td><td></td><td></td></tr><tr><td>RelAP-2</td><td>CATCATGCGATATTCCACA</td><td>443</td><td><i>relAP</i></td></tr><tr><td>crdRP-1</td><td>GCGGCGATCCTAAATGTGAC</td><td></td><td></td></tr><tr><td>crdRP-2</td><td>CATGCGGTCCTGACACTCG</td><td>466</td><td><i>crdRP</i></td></tr><tr><td>crdSP-1</td><td>TCGGTCGGCACATGGGTCAAT</td><td></td><td></td></tr><tr><td>crdSP-2</td><td>CATCGCCCTAACCTCGCAGT</td><td>446</td><td><i>crdSP</i></td></tr></table>	<table><tr><td>Primer name</td><td>Oligonucleotide</td><td>Product length</td><td>Product name</td></tr><tr><td>crdPG-1</td><td>GTACTCGAGATTGTCGGCAGTCCAG</td><td>607</td><td>crdP</td></tr><tr><td>crdPG-2</td><td>AGCTCCTCGCCCTTGCTCACCATGAAATCAACTCCTCTGT</td><td></td><td></td></tr><tr><td>GFP-1</td><td>ACAGAGGAGTTGATTTCATGGTGAGCAAGGGCGAGGAGCT</td><td>746</td><td>GFP</td></tr><tr><td>GFP-2</td><td>CGCGGATCCTTACTTGTACAGCTCGTCCATG</td><td></td><td>crdP</td></tr><tr><td>crdP-1</td><td>TCACCAACACCAACTCTGGA</td><td></td><td></td></tr></table>	<table><tr><td>Primer name</td><td>Oligonucleotide</td><td>Product length</td><td>Product name</td></tr><tr><td>crdP-2</td><td>CATGAAATCAACTCCTCTGT</td><td>607</td><td>crdP</td></tr><tr><td>crdP142-1</td><td>ATCGTCAGATGCCTATTTGT</td><td>537</td><td>crdP</td></tr><tr><td>crdP108-1</td><td>AAATTAGTTAATGCAAT</td><td>503</td><td>crdP</td></tr><tr><td>crdP98-1</td><td>TTAATGCAATTTTTACTATGTT</td><td>493</td><td>crdP</td></tr><tr><td>crdP53-1</td><td>CCATTTCAATACTGCGGGAGG</td><td>448</td><td>crdP</td></tr><tr><td>crdP13-1</td><td>AGGAGTTGATTTCATGCTGTT</td><td>408</td><td>crdP</td></tr><tr><td>crdP1-1</td><td>ATGCTGTTCCGCAATAAG</td><td>395</td><td>crdA</td></tr><tr><td>crdA395-2</td><td>TCGGTCCGCAGCAGCAAAG</td><td></td><td></td></tr><tr><td>q-crdA-1</td><td>CAAGGCATAAGCGAAGACATC</td><td>227</td><td>crdA</td></tr><tr><td>q-crdA-2</td><td>CTCCGTGTTTCAAGTGTGGTC</td><td></td><td></td></tr><tr><td>q-crdS-1</td><td>AACCTGACGATTGCGATTGGG</td><td>179</td><td>crdS</td></tr><tr><td>q-crdS-2</td><td>GTGTAGCACCAGAGCGTTTCG</td><td></td><td></td></tr><tr><td>q-crdC-1</td><td>GTTCGGTCAGGATGCTCAAC</td><td>248</td><td>crdC</td></tr><tr><td>q-crdC-2</td><td>GCCAAAGTTCGGAATCAATG</td><td></td><td></td></tr><tr><td>crdR-1</td><td>GCCAGATCTATGACCGAGAATAAGAAAAAGCCT</td><td>437</td><td>crdR</td></tr><tr><td>crdR-2</td><td>TTGAGCTCTTACTCGGCGTCGCCTTCG</td><td></td><td></td></tr><tr><td>NcrdR-1</td><td>ACACTCGAGATACACCCGGTCCCTACCAGCATT</td><td></td><td>crdR</td></tr><tr><td>NcrdR-2</td><td>TTTGAGCTCCTTGTCCTTCTTCAGAAGCGTGT</td><td>1302</td><td>crdR</td></tr><tr><td>q-crdR-1</td><td>TCGGAATGAGCCAGGAGAAGC</td><td>238</td><td>crdR</td></tr><tr><td>q-crdR-2</td><td>TCAGCCGAGGACAGAAAGTCG</td><td></td><td></td></tr><tr><td>crdRup-1</td><td>TCTGAGCTCTTCGGCGTTTCGGAATGGTTG</td><td>2533</td><td>CrdR</td></tr><tr><td>crdRdown-2</td><td>CAACACAAGCTTAACCGTCACCTGGCTCTTGGCA</td><td></td><td></td></tr><tr><td>crdRcheckGm-2</td><td>TTGGGCATACGGGAAGAAGT</td><td>558</td><td>Gm</td></tr><tr><td>crdRcheckGm-1</td><td>CGGCTGATGTTGGGAGTAGG</td><td>577</td><td></td></tr><tr><td>Rep-Kan-1</td><td>ACGCGTCGACCTTGCCAGCCCGTGGATAT</td><td>3266</td><td>Km</td></tr><tr><td>Rep-Kan-2</td><td>ACGCGTCGACTCTGTGATGGCTTCCATGTC</td><td></td><td></td></tr><tr><td>Gm-1</td><td>ATAGTTGTCGAGATATTCACTAGTCGTCAGGTGGCACTTTTCG</td><td>1302</td><td>Gm</td></tr><tr><td>Gm-2</td><td>CGCGGATCCGCTCTGCTGAAGCCAGTTAC</td><td></td><td></td></tr><tr><td>celAP1</td><td>ACCCGGTCTATCCCATGA</td><td></td><td></td></tr><tr><td>celAP-2</td><td>CATCCAGAAACTTTCCGT</td><td>441</td><td>celAP</td></tr><tr><td>relAP-1</td><td>CCAGATTTCTCAAGGGTC</td><td></td><td></td></tr><tr><td>RelAP-2</td><td>CATCATGCGATATTCCACA</td><td>443</td><td>relAP</td></tr><tr><td>crdRP-1</td><td>GCGGCGATCCTAAATGTGAC</td><td></td><td></td></tr><tr><td>crdRP-2</td><td>CATGCGGTCCTGACACTCG</td><td>466</td><td>crdRP</td></tr><tr><td>crdSP-1</td><td>TCGGTCGGCACATGGGTCAAT</td><td></td><td></td></tr><tr><td>crdSP-2</td><td>CATCGCCCTAACCTCGCAGT</td><td>446</td><td>crdSP</td></tr></table>
02fa9e3b3695bb07995a91c076ffd9114130a8bef740627554a03214d9a49819.png	simple	<table><tr><td>lectin</td><td>time (dpi/dpe)<sup>a</sup></td><td>mucus<sup>b</sup></td><td>SMC<sup>c</sup></td><td>MNC<sup>d</sup></td></tr><tr><td>UEAI</td><td>0</td><td>+/-</td><td>-</td><td>++</td></tr><tr><td></td><td>14</td><td>+/-</td><td>+/-</td><td>++</td></tr><tr><td></td><td>21</td><td>+</td><td>+</td><td>++</td></tr><tr><td></td><td>60</td><td>+</td><td>+</td><td>++</td></tr><tr><td>WGA</td><td>0</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>14</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>21</td><td>+</td><td>+</td><td>+</td></tr><tr><td></td><td>60</td><td>+</td><td>+</td><td>+</td></tr><tr><td>RCA120</td><td>0</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>14</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>21</td><td>++</td><td>++</td><td>+</td></tr><tr><td></td><td>60</td><td>++</td><td>++</td><td>++</td></tr><tr><td>DBA</td><td>0</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>14</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>21</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>60</td><td>+</td><td>+</td><td>++</td></tr><tr><td>SBA</td><td>0</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>14</td><td>++</td><td>+</td><td>++</td></tr><tr><td></td><td>21</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>60</td><td>++</td><td>++</td><td>++</td></tr><tr><td>PNA</td><td>0</td><td>+</td><td>++</td><td>++</td></tr><tr><td></td><td>14</td><td>+</td><td>+</td><td>++</td></tr><tr><td></td><td>21</td><td>+/-</td><td>+/-</td><td>+/-</td></tr><tr><td></td><td>60</td><td>+</td><td>+</td><td>++</td></tr></table>	<table><tr><td>lectin</td><td>time (dpi/dpe)a</td><td>mucusb</td><td>SMCc</td><td>MNCd</td></tr><tr><td>UEAI</td><td>0</td><td>+/-</td><td>-</td><td>++</td></tr><tr><td></td><td>14</td><td>+/-</td><td>+/-</td><td>++</td></tr><tr><td></td><td>21</td><td>+</td><td>+</td><td>++</td></tr><tr><td></td><td>60</td><td>+</td><td>+</td><td>++</td></tr></table>	<table><tr><td>WGA</td><td>0</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>14</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>21</td><td>+</td><td>+</td><td>+</td></tr><tr><td></td><td>60</td><td>+</td><td>+</td><td>+</td></tr><tr><td>RCA120</td><td>0</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>14</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>21</td><td>++</td><td>++</td><td>+</td></tr><tr><td></td><td>60</td><td>++</td><td>++</td><td>++</td></tr><tr><td>DBA</td><td>0</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>14</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>21</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>60</td><td>+</td><td>+</td><td>++</td></tr><tr><td>SBA</td><td>0</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>14</td><td>++</td><td>+</td><td>++</td></tr><tr><td></td><td>21</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>60</td><td>++</td><td>++</td><td>++</td></tr><tr><td>PNA</td><td>0</td><td>+</td><td>++</td><td>++</td></tr><tr><td></td><td>14</td><td>+</td><td>+</td><td>++</td></tr><tr><td></td><td>21</td><td>+/-</td><td>+/-</td><td>+/-</td></tr><tr><td></td><td>60</td><td>+</td><td>+</td><td>++</td></tr></table>
405ee029d57ac9a6a14682fb572ab9fbf106ca3f216a07d6bd2bb2349c5c39f1.png	complex	<table><tr><td rowspan="2">HRV Index</td><td rowspan="2">Sitting Variable</td><td colspan="4">Crude Model (<i>N</i> = 126)</td><td colspan="4">Primary Adjusted Model (<i>N</i> = 126)</td></tr><tr><td>B</td><td>95%CI Low</td><td>High</td><td><i>p</i></td><td>B</td><td>95%CI Low</td><td>High</td><td><i>p</i></td></tr><tr><td>IBI (ms)</td><td>Occupational sitting</td><td>−17.00</td><td>−35.80</td><td>1.81</td><td>0.08</td><td>−24.24</td><td>−46.98</td><td>−1.50</td><td>0.04</td></tr><tr><td></td><td>Leisure-time sitting</td><td>6.80</td><td>−7.97</td><td>21.57</td><td>0.36</td><td>0.41</td><td>−14.43 </td><td>−15.25</td><td>0.96</td></tr><tr><td>RMSSD (ms)</td><td>Occupational sitting</td><td>−3.26</td><td>0.06</td><td>−6.66</td><td>0.14</td><td>−4.96</td><td>−8.88</td><td>−1.05</td><td>0.01</td></tr><tr><td></td><td>Leisure-time sitting</td><td>0.16</td><td>0.91</td><td>−2.51</td><td>2.83</td><td>1.83</td><td>−0.73</td><td>4.38</td><td>0.16</td></tr><tr><td>SDNN (ms)</td><td>Occupational sitting</td><td>−3.03</td><td>−5.87</td><td>−0.20</td><td>0.04</td><td>−5.07</td><td>−8.48</td><td>−1.67</td><td>0.00</td></tr><tr><td></td><td>Leisure-time sitting</td><td>0.46</td><td>−1.77</td><td>2.69</td><td>0.68</td><td>1.10</td><td>−1.12</td><td>3.33</td><td>0.33</td></tr><tr><td>ln VLF</td><td>Occupational sitting</td><td>−0.10</td><td>−0.20</td><td>0.01</td><td>0.06</td><td>−0.19</td><td>−0.32</td><td>−0.05</td><td>0.01</td></tr><tr><td></td><td>Leisure-time sitting</td><td>0.03</td><td>−0.05</td><td>0.11</td><td>0.50</td><td>0.00</td><td>−0.09</td><td>0.09</td><td>0.98</td></tr><tr><td>ln LF</td><td>Occupational sitting</td><td>−0.13</td><td>−0.25</td><td>−0.01</td><td>0.03</td><td>−0.18</td><td>−0.32</td><td>−0.04</td><td>0.01</td></tr><tr><td></td><td>Leisure-time sitting</td><td>0.05</td><td>−0.04</td><td>0.14</td><td>0.30</td><td>0.07</td><td>−0.02</td><td>0.17</td><td>0.11</td></tr><tr><td>ln HF</td><td>Occupational sitting</td><td>−0.12</td><td>−0.26</td><td>0.03</td><td>0.12</td><td>−0.12</td><td>−0.27</td><td>0.04</td><td>0.14</td></tr><tr><td></td><td>Leisure-time sitting</td><td>0.00</td><td>−0.12</td><td>0.11</td><td>0.95</td><td>0.08</td><td>−0.02</td><td>0.19</td><td>0.13</td></tr><tr><td>ln LF/HF</td><td>Occupational sitting</td><td>−0.01</td><td>−0.12</td><td>0.10</td><td>0.91</td><td>−0.03</td><td>−0.17</td><td>0.10</td><td>0.62</td></tr><tr><td></td><td>Leisure-time sitting</td><td>0.06</td><td>−0.03</td><td>0.14</td><td>0.19</td><td>−0.01</td><td>−0.09</td><td>0.08</td><td>0.92</td></tr></table>	<table><tr><td rowspan="2">HRV Index</td><td rowspan="2">Sitting Variable</td><td colspan="4">Crude Model (N = 126)</td><td>Primary Adjusted Model (N = 126)</td></tr><tr><td>B</td><td>95%CI Low</td><td>High</td><td>p</td><td>B</td></tr><tr><td>IBI (ms)</td><td>Occupational sitting</td><td>−17.00</td><td>−35.80</td><td>1.81</td><td>0.08</td><td>−24.24</td></tr><tr><td></td><td>Leisure-time sitting</td><td>6.80</td><td>−7.97</td><td>21.57</td><td>0.36</td><td>0.41</td></tr><tr><td>RMSSD (ms)</td><td>Occupational sitting</td><td>−3.26</td><td>0.06</td><td>−6.66</td><td>0.14</td><td>−4.96</td></tr><tr><td></td><td>Leisure-time sitting</td><td>0.16</td><td>0.91</td><td>−2.51</td><td>2.83</td><td>1.83</td></tr><tr><td>SDNN (ms)</td><td>Occupational sitting</td><td>−3.03</td><td>−5.87</td><td>−0.20</td><td>0.04</td><td>−5.07</td></tr><tr><td></td><td>Leisure-time sitting</td><td>0.46</td><td>−1.77</td><td>2.69</td><td>0.68</td><td>1.10</td></tr><tr><td>ln VLF</td><td>Occupational sitting</td><td>−0.10</td><td>−0.20</td><td>0.01</td><td>0.06</td><td>−0.19</td></tr><tr><td></td><td>Leisure-time sitting</td><td>0.03</td><td>−0.05</td><td>0.11</td><td>0.50</td><td>0.00</td></tr><tr><td>ln LF</td><td>Occupational sitting</td><td>−0.13</td><td>−0.25</td><td>−0.01</td><td>0.03</td><td>−0.18</td></tr><tr><td></td><td>Leisure-time sitting</td><td>0.05</td><td>−0.04</td><td>0.14</td><td>0.30</td><td>0.07</td></tr><tr><td>ln HF</td><td>Occupational sitting</td><td>−0.12</td><td>−0.26</td><td>0.03</td><td>0.12</td><td>−0.12</td></tr><tr><td></td><td>Leisure-time sitting</td><td>0.00</td><td>−0.12</td><td>0.11</td><td>0.95</td><td>0.08</td></tr><tr><td>ln LF/HF</td><td>Occupational sitting</td><td>−0.01</td><td>−0.12</td><td>0.10</td><td>0.91</td><td>−0.03</td></tr><tr><td></td><td>Leisure-time sitting</td><td>0.06</td><td>−0.03</td><td>0.14</td><td>0.19</td><td>−0.01</td></tr></table>	<table><tr><td colspan="3">Primary Adjusted Model (N = 126)</td></tr><tr><td>95%CI Low</td><td>High</td><td>p</td></tr><tr><td>−46.98</td><td>−1.50</td><td>0.04</td></tr><tr><td>−14.43</td><td>−15.25</td><td>0.96</td></tr><tr><td>−8.88</td><td>−1.05</td><td>0.01</td></tr><tr><td>−0.73</td><td>4.38</td><td>0.16</td></tr><tr><td>−8.48</td><td>−1.67</td><td>0.00</td></tr><tr><td>−1.12</td><td>3.33</td><td>0.33</td></tr><tr><td>−0.32</td><td>−0.05</td><td>0.01</td></tr><tr><td>−0.09</td><td>0.09</td><td>0.98</td></tr><tr><td>−0.32</td><td>−0.04</td><td>0.01</td></tr><tr><td>−0.02</td><td>0.17</td><td>0.11</td></tr><tr><td>−0.27</td><td>0.04</td><td>0.14</td></tr><tr><td>−0.02</td><td>0.19</td><td>0.13</td></tr><tr><td>−0.17</td><td>0.10</td><td>0.62</td></tr><tr><td>−0.09</td><td>0.08</td><td>0.92</td></tr></table>
f631aa3f4a2f8daf322cde303f21a16276a8cd29ecd8e1517ca0b835913511a4.png	complex	<table><tr><td rowspan="2"></td><td colspan="2">24‐hr mean <i>T</i><sub>b</sub> (°C)</td><td colspan="2">24‐hr maximum <i>T</i><sub>b</sub> (°C)</td></tr><tr><td>No feed</td><td>Feed</td><td>No feed</td><td>Feed</td></tr><tr><td colspan="5"><i>Sex</i></td></tr><tr><td>Male (<i>n</i> = 10)</td><td>37.4 ± 0.1</td><td>37.8 ± 0.2</td><td>38.3 ± 0.2</td><td>38.8 ± 0.2</td></tr><tr><td>Female (<i>n</i> = 3)</td><td>37.6 ± 0.2</td><td>37.9 ± 0.2</td><td>38.5 ± 0.4</td><td>39.1 ± 0.3</td></tr></table>	<table><tr><td rowspan="2"></td><td colspan="2">24‐hr mean Tb (°C)</td><td colspan="2">24‐hr maximum Tb (°C)</td></tr><tr><td>No f</td><td>Fee</td><td>No fe</td><td>Feed</td></tr></table>	<table><tr><td></td><td>eed</td><td>d</td><td>ed</td><td></td></tr><tr><td colspan="5">Sex</td></tr><tr><td>Male (n = 10)</td><td>37.4 ± 0.1</td><td>37.8 ± 0.2</td><td>38.3 ± 0.2</td><td>38.8 ± 0.2</td></tr><tr><td>Female (n = 3)</td><td>37.6 ± 0.2</td><td>37.9 ± 0.2</td><td>38.5 ± 0.4</td><td>39.1 ± 0.3</td></tr></table>
50a94dab4a1ce3e9c4e4b57a2e32f154c819b6005ae34e90eab5c91d6211678d.png	complex	<table><tr><td></td><td></td><td colspan="2">Intervention (home visit)</td><td></td></tr><tr><td>Variable</td><td></td><td>No (<i>N</i> = 221)</td><td>Yes (<i>N</i> = 262)</td><td><i>P</i>-value</td></tr><tr><td colspan="5">Age (years)</td></tr><tr><td></td><td>Age (±SD)</td><td>30.40 ± 8.57</td><td>30.49 ± 7.84</td><td>0.90</td></tr><tr><td colspan="5">Education (N, %)</td></tr><tr><td></td><td>None</td><td>14 (6.33 %)</td><td>7 (2.67 %)</td><td rowspan="4">0.06</td></tr><tr><td></td><td>Primary level</td><td>94 (42.53 %)</td><td>98 (37.40 %)</td></tr><tr><td></td><td>Secondary level</td><td>91 (41.18 %)</td><td>117 (44.66 %)</td></tr><tr><td></td><td>Tertiary level</td><td>22 (9.95 %)</td><td>40 (15.27 %)</td></tr><tr><td colspan="5">Religion (N, %)</td></tr><tr><td></td><td>Catholic</td><td>116 (52.49 %)</td><td>131 (50.00 %)</td><td rowspan="5">0.03</td></tr><tr><td></td><td>Baptist</td><td>35 (15.84 %)</td><td>22 (8.40 %)</td></tr><tr><td></td><td>Presbyterian</td><td>32 (14.48 %)</td><td>53 (20.23 %)</td></tr><tr><td></td><td>Pentecostal</td><td>0 %</td><td>3 (1.15 %)</td></tr><tr><td></td><td>Muslim</td><td>38 (17.19 %)</td><td>53 (20.23 %)</td></tr><tr><td colspan="5">Marital status (N,%)</td></tr><tr><td></td><td>Single</td><td>39 (17.65 %)</td><td>48 (18.32 %)</td><td rowspan="4">0.25</td></tr><tr><td></td><td>Married</td><td>164 (74.21 %)</td><td>195 (74.43 %)</td></tr><tr><td></td><td>separated/divorced</td><td>15 (6.79 %)</td><td>10 (3.82 %)</td></tr><tr><td></td><td>Widowed</td><td>3 (1.36 %)</td><td>9 (3.44 %)</td></tr><tr><td colspan="5">Occupation (N, %)</td></tr><tr><td></td><td>Unemployed</td><td>80 (36.20 %)</td><td>98 (37.40 %)</td><td rowspan="2">0.78</td></tr><tr><td></td><td>Employed</td><td>141 (63.8 %)</td><td>164 (62.60 %)</td></tr><tr><td colspan="5">Number of children (N, %)</td></tr><tr><td></td><td>0–2</td><td>95 (42.99 %)</td><td>126 (57.01 %)</td><td rowspan="2">0.54</td></tr><tr><td></td><td>3 > 5</td><td>120 (45.80 %)</td><td>142 (54.20 %)</td></tr></table>	<table><tr><td></td><td></td><td colspan="2">Intervention (home visit)</td><td></td></tr><tr><td>Variable</td><td></td><td>No (N = 221)</td><td>Yes (N = 262)</td><td>P-value</td></tr><tr><td colspan="5">Age (years)</td></tr><tr><td></td><td>Age (±SD)</td><td>30.40 ± 8.57</td><td>30.49 ± 7.84</td><td>0.90</td></tr><tr><td colspan="5">Education (N, %)</td></tr><tr><td></td><td>None</td><td>14 (6.33 %)</td><td>7 (2.67 %)</td><td rowspan="4">0.06</td></tr><tr><td></td><td>Primary level</td><td>94 (42.53 %)</td><td>98 (37.40 %)</td></tr><tr><td></td><td>Secondary level</td><td>91 (41.18 %)</td><td>117 (44.66 %)</td></tr><tr><td></td><td>Tertiary level</td><td>22 (9.95 %)</td><td>40 (15.27 %)</td></tr><tr><td colspan="5">Religion (N, %)</td></tr><tr><td></td><td>Catholic</td><td>116 (52.49 %)</td><td>131 (50.00 %)</td><td rowspan="5">0.03</td></tr><tr><td></td><td>Baptist</td><td>35 (15.84 %)</td><td>22 (8.40 %)</td></tr><tr><td></td><td>Presbyterian</td><td>32 (14.48 %)</td><td>53 (20.23 %)</td></tr><tr><td></td><td>Pentecostal</td><td>0 %</td><td>3 (1.15 %)</td></tr><tr><td></td><td>Muslim</td><td>38 (17.19 %)</td><td>53 (20.23 %)</td></tr><tr><td colspan="5">Marital status (N,%)</td></tr><tr><td></td><td>Single</td><td>39 (17.65 %)</td><td>48 (18.32 %)</td><td rowspan="4">0.25</td></tr><tr><td></td><td>Married</td><td>164 (74.21 %)</td><td>195 (74.43 %)</td></tr><tr><td></td><td>separated/divorced</td><td>15 (6.79 %)</td><td>10 (3.82 %)</td></tr><tr><td></td><td>Widowed</td><td>3 (1.36 %)</td><td>9 (3.44 %)</td></tr><tr><td colspan="5">Occupation (N, %)</td></tr><tr><td></td><td>Unemployed</td><td>80 (36.20 %)</td><td>98 (37.40 %)</td><td>0.78</td></tr></table>	<table><tr><td></td><td>Employed</td><td>141 (63.8 %)</td><td>164 (62.60 %)</td><td>0.78</td></tr><tr><td colspan="5">Number of children (N, %)</td></tr><tr><td></td><td>0–2</td><td>95 (42.99 %)</td><td>126 (57.01 %)</td><td rowspan="2">0.54</td></tr><tr><td></td><td>3 > 5</td><td>120 (45.80 %)</td><td>142 (54.20 %)</td></tr></table>
0c83a1147e3740adb25b22a353b46b90d5501549ebe45119e05a4d5f5eeb6940.png	simple	<table><tr><td>Preparation</td><td>Average finish line width (mm)</td></tr><tr><td>CCC 46</td><td>0.5</td></tr><tr><td>MCC 24</td><td>(0.5 + 1.2)/2 = 0.85</td></tr><tr><td>MCC 46</td><td>(0.5 + 0.8)/2 = 0.65</td></tr><tr><td>ACC 21</td><td>1</td></tr></table>	<table><tr><td>Preparation</td></tr><tr><td>CCC 46</td></tr><tr><td>MCC 24</td></tr><tr><td>MCC 46</td></tr><tr><td>ACC 21</td></tr></table>	<table><tr><td>Average finish line width (mm)</td></tr><tr><td>0.5</td></tr><tr><td>(0.5 + 1.2)/2 = 0.85</td></tr><tr><td>(0.5 + 0.8)/2 = 0.65</td></tr><tr><td>1</td></tr></table>
685a7b6d4c8cab5d594648324ae46b7d3c3a714af7c620f7010a241bceb3ce16.png	complex	<table><tr><td rowspan="2">Peptide</td><td colspan="3">COX-1</td><td colspan="3">COX-2</td></tr><tr><td>be</td><td>ir</td><td>hb</td><td>be</td><td>ir</td><td>hb</td></tr><tr><td>GMD</td><td>−1.20</td><td>23</td><td>1</td><td>−39.87</td><td>21</td><td>3</td></tr><tr><td>GHE</td><td>−0.56</td><td>25</td><td>0</td><td>−42.15</td><td>26</td><td>5</td></tr><tr><td>YYV</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td></tr></table>	<table><tr><td rowspan="2">Peptide</td><td colspan="2">COX-1</td></tr><tr><td>be</td><td>ir</td></tr><tr><td>GMD</td><td>−1.20</td><td>23</td></tr><tr><td>GHE</td><td>−0.56</td><td>25</td></tr><tr><td>YYV</td><td>—</td><td>—</td></tr></table>	<table><tr><td>COX-1</td><td colspan="3">COX-2</td></tr><tr><td>hb</td><td>be</td><td>ir</td><td>hb</td></tr><tr><td>1</td><td>−39.87</td><td>21</td><td>3</td></tr><tr><td>0</td><td>−42.15</td><td>26</td><td>5</td></tr><tr><td>—</td><td>—</td><td>—</td><td>—</td></tr></table>
e2397db4488c776e18dd9b47f396e2202806fccd8849626da8a98eb717712f27.png	complex	<table><tr><td>Antibody</td><td colspan="4">Growth inhibition (%) over the period of cultivation</td></tr><tr><td>1 mg/ml IgG</td><td colspan="4"></td></tr><tr><td></td><td>Day 1</td><td>Day 2</td><td>Day 3</td><td>Day 4</td></tr><tr><td>GST</td><td>9.5±9.9</td><td>5.3±5.5</td><td>10.7±7.4</td><td>10.5±3.7</td></tr><tr><td>BbTRAP2</td><td>55.3±6.1<sup><i></i></sup></td><td>48.1±5.6<sup><i></i></sup></td><td>59.1±4.4<sup><i></i></sup>, <sup><i></i></sup></td><td>73.6±4<sup><i></i></sup>, <sup><i>*</i></sup></td></tr><tr><td>BbRAP-1CT</td><td>54.2±9.1<sup><i></i></sup></td><td>45.9±8.2<sup><i></i></sup></td><td>45.3±4.7<sup><i></i></sup></td><td>60.9±5.4<sup><i></i></sup></td></tr><tr><td>BbMSA-2c</td><td>19.2±17.9</td><td>17.7±8.2</td><td>26.1±8.9<sup><i></i></sup></td><td>43.1±5<sup><i>*</i></sup></td></tr></table>	<table><tr><td>Antibody</td><td colspan="4">Growth inhibition (%) over the period of cultivation</td></tr><tr><td>1 mg/ml IgG</td><td colspan="4"></td></tr><tr><td></td><td>Day 1</td><td>Day 2</td><td>Day 3</td><td>Day 4</td></tr></table>	<table><tr><td>GST</td><td>9.5±9.9</td><td>5.3±5.5</td><td>10.7±7.4</td><td>10.5±3.7</td></tr><tr><td>BbTRAP2</td><td>55.3±6.1</td><td>48.1±5.6</td><td>59.1±4.4, </td><td>73.6±4, *</td></tr><tr><td>BbRAP-1CT</td><td>54.2±9.1</td><td>45.9±8.2</td><td>45.3±4.7</td><td>60.9±5.4</td></tr><tr><td>BbMSA-2c</td><td>19.2±17.9</td><td>17.7±8.2</td><td>26.1±8.9</td><td>43.1±5*</td></tr></table>
7a0b5fc576fcc9ae4b83f9df105978c8d3efdc33dede17bd460f67298966d80d.png	simple	<table><tr><td>TB CX-test</td><td>AFB staining (+)</td><td>AFB staining (−)</td><td>Totals</td></tr><tr><td>TB CX-test(+)</td><td>12</td><td>1*</td><td>13</td></tr><tr><td>TB CX-test(−)</td><td>0</td><td>83</td><td>83</td></tr><tr><td>Totals</td><td>12</td><td>84</td><td>96</td></tr></table>	<table><tr><td>TB CX-test</td><td>AFB staining (+)</td><td>AFB staining (−)</td><td>Totals</td></tr><tr><td>TB CX-test(+)</td><td>12</td><td>1*</td><td>13</td></tr><tr><td>TB CX-test(−)</td><td>0</td><td>83</td><td>83</td></tr></table>	<table><tr><td>Totals</td><td>12</td><td>84</td><td>96</td></tr></table>
e370057b32d6f60868bff32a5daec331bcc6d4c058c4d953f70287c461f096d1.png	simple	<table><tr><td><i>Variable</i></td><td><i>Max</i></td><td><i>Min</i></td><td><i>Mean</i></td><td><i>SD</i></td></tr><tr><td>“Income”</td><td>550.00</td><td>0.00</td><td>42.33</td><td>42.65</td></tr><tr><td>“Spent”</td><td>425.00</td><td>1.97</td><td>25.42</td><td>36.86</td></tr><tr><td>“Pins”</td><td>0.90</td><td>0.00</td><td>0.58</td><td>0.23</td></tr></table>	<table><tr><td>Variable</td><td>Max</td><td>Min</td><td>Mean</td><td>SD</td></tr><tr><td>“Income”</td><td>550.00</td><td>0.00</td><td>42.33</td><td>42.65</td></tr><tr><td>“Spent”</td><td>425.00</td><td>1.97</td><td>25.42</td><td>36.86</td></tr></table>	<table><tr><td>“Pins”</td><td>0.90</td><td>0.00</td><td>0.58</td><td>0.23</td></tr></table>
650ddc8f908c2530ed6ffa1d7f2d5e9905654600a7f16d9ef827c1e527bc1bb3.png	simple	<table><tr><td>Variables</td><td>Mean</td><td>95% CI of the mean</td><td>Statistics (<i>P</i> values)</td></tr><tr><td>IBS symptom score</td><td>1.57</td><td>0.10; 3.05</td><td><i>P</i> = 0.04</td></tr><tr><td>Bacteroides</td><td>−0.01</td><td>−0.11; 0.08</td><td>ns (<i>P</i> = 0.77)</td></tr><tr><td>Faecalibacterium</td><td>−0.03</td><td>−0.18; 0.12</td><td>ns (<i>P</i> = 0.63)</td></tr><tr><td>Lachnospiraceae</td><td>0.05</td><td>−0.03; 0.13</td><td>ns (<i>P</i> = 0.18)</td></tr><tr><td>“Common” Simpson's D</td><td>−0.04</td><td>−0.15; 0.08</td><td>ns (<i>P</i> = 0.50)</td></tr></table>	<table><tr><td>Variables</td><td>Mean</td><td>95% CI of the mean</td><td>Statistics (P values)</td></tr><tr><td>IBS symptom score</td><td>1.57</td><td>0.10; 3.05</td><td>P = 0.04</td></tr><tr><td>Bacteroides</td><td>−0.01</td><td>−0.11; 0.08</td><td>ns (P = 0.77)</td></tr><tr><td>Faecalibacterium</td><td>−0.03</td><td>−0.18; 0.12</td><td>ns (P = 0.63)</td></tr></table>	<table><tr><td>Lachnospiraceae</td><td>0.05</td><td>−0.03; 0.13</td><td>ns (P = 0.18)</td></tr><tr><td>“Common” Simpson's D</td><td>−0.04</td><td>−0.15; 0.08</td><td>ns (P = 0.50)</td></tr></table>
9744cc1ccdf3131f2a22be41f3eb022036e9ee8e4459906d8fa10ccf0fdb7b50.png	complex	<table><tr><td rowspan="2"> </td><td rowspan="2">I</td><td colspan="4"><i>T</i><sub>a </sub>(°C)</td></tr><tr><td>400</td><td>450</td><td>500</td><td>550</td></tr><tr><td rowspan="4">Average height (AH) [nm]</td><td>(111)A</td><td>23.4</td><td>25.4</td><td>28.9</td><td>32.2</td></tr><tr><td>(110)</td><td>22.6</td><td>24.7</td><td>28.2</td><td>31.2</td></tr><tr><td>(100)</td><td>21.7</td><td>24.0</td><td>26.7</td><td>29.7</td></tr><tr><td>(111)B</td><td>19.9</td><td>22.3</td><td>25.2</td><td>27.8</td></tr><tr><td rowspan="4">Average lateral diameter (LD) [nm]</td><td>(111)A</td><td>128.6</td><td>133.8</td><td>138.5</td><td>143.4</td></tr><tr><td>(110)</td><td>122.5</td><td>128</td><td>133.8</td><td>141</td></tr><tr><td>(100)</td><td>115</td><td>124.5</td><td>130.8</td><td>139.1</td></tr><tr><td>(111)B</td><td>106.2</td><td>115.5</td><td>123.5</td><td>133.1</td></tr><tr><td rowspan="4">Average density (AD) [×10<sup>8</sup> cm<sup>−2</sup>]</td><td>(111)A</td><td>139</td><td>123</td><td>110</td><td>99</td></tr><tr><td>(110)</td><td>148</td><td>131</td><td>118</td><td>107</td></tr><tr><td>(100)</td><td>160</td><td>141</td><td>129</td><td>119</td></tr><tr><td>(111)B</td><td>173</td><td>150</td><td>140</td><td>132</td></tr></table>	<table><tr><td rowspan="2"></td><td rowspan="2">I</td><td colspan="4">Ta (°C)</td></tr><tr><td>400</td><td>450</td><td>500</td><td>550</td></tr><tr><td rowspan="4">Average height (AH) [nm]</td><td>(111)A</td><td>23.4</td><td>25.4</td><td>28.9</td><td>32.2</td></tr><tr><td>(110)</td><td>22.6</td><td>24.7</td><td>28.2</td><td>31.2</td></tr><tr><td>(100)</td><td>21.7</td><td>24.0</td><td>26.7</td><td>29.7</td></tr><tr><td>(111)B</td><td>19.9</td><td>22.3</td><td>25.2</td><td>27.8</td></tr><tr><td rowspan="2">Average latera</td><td>(111)A</td><td>128.6</td><td>133.8</td><td>138.5</td><td>143.4</td></tr><tr><td>(</td><td>12</td><td>128</td><td></td><td>141</td></tr></table>	<table><tr><td rowspan="3">l diameter (LD) [nm]</td><td>110)</td><td>2.5</td><td></td><td>133.8</td><td></td></tr><tr><td>(100)</td><td>115</td><td>124.5</td><td>130.8</td><td>139.1</td></tr><tr><td>(111)B</td><td>106.2</td><td>115.5</td><td>123.5</td><td>133.1</td></tr><tr><td rowspan="4">Average density (AD) [×108 cm−2]</td><td>(111)A</td><td>139</td><td>123</td><td>110</td><td>99</td></tr><tr><td>(110)</td><td>148</td><td>131</td><td>118</td><td>107</td></tr><tr><td>(100)</td><td>160</td><td>141</td><td>129</td><td>119</td></tr><tr><td>(111)B</td><td>173</td><td>150</td><td>140</td><td>132</td></tr></table>
0b4dd4d3b07343a19c30729e888aaf106bfe31b96a570c698e8f8a66fb30f033.png	complex	<table><tr><td>Reason</td><td>No. of patients</td><td>% patients</td></tr><tr><td colspan="3">Presence of any types of primary disease progression (n = 26)</td></tr><tr><td>Enlargement of tumor</td><td>14</td><td>47</td></tr><tr><td>Elevation of tumor marker</td><td>7</td><td>23</td></tr><tr><td>Carcinomatous pain</td><td>5</td><td>17</td></tr><tr><td>Obstructive jaundice</td><td>5</td><td>17</td></tr><tr><td>Duodenal hemorrhage</td><td>2</td><td>7</td></tr><tr><td colspan="3">Absence of disease progression (n = 4)</td></tr><tr><td>Interstitial pneumonia</td><td>4</td><td>13</td></tr></table>	<table><tr><td>Reason</td><td>No. of patients</td></tr><tr><td colspan="2">Presence of any types of primary disease progression (n = 26)</td></tr><tr><td>Enlargement of tumor</td><td>14</td></tr><tr><td>Elevation of tumor marker</td><td>7</td></tr><tr><td>Carcinomatous pain</td><td>5</td></tr><tr><td>Obstructive jaundice</td><td>5</td></tr><tr><td>Duodenal hemorrhage</td><td>2</td></tr><tr><td colspan="2">Absence of disease progression (n = 4)</td></tr><tr><td>Interstitial pneumonia</td><td>4</td></tr></table>	<table><tr><td>% patients</td></tr><tr><td>Presence of any types of primary disease progression (n = 26)</td></tr><tr><td>47</td></tr><tr><td>23</td></tr><tr><td>17</td></tr><tr><td>17</td></tr><tr><td>7</td></tr><tr><td>Absence of disease progression (n = 4)</td></tr><tr><td>13</td></tr></table>
ec07a5032d8702ce95565fabfba065ee781e5613a275cc64c5ecd2c02e310db6.png	simple	<table><tr><td>Antibodies</td><td>Manufacturer</td><td>Source</td><td>Reactivity</td><td>Dilution</td></tr><tr><td>CD34</td><td>Sigma</td><td>Mouse</td><td>Rat</td><td>1:100</td></tr><tr><td>5-HT</td><td>Immunostar</td><td>Rabbit</td><td>Rat</td><td>1:20,000</td></tr><tr><td>GFAP</td><td>Millipore</td><td>Rabbit</td><td>Rat</td><td>1:50</td></tr><tr><td>APC</td><td>Calbiochem</td><td>Mouse</td><td>Rat</td><td>1:200</td></tr><tr><td>NeuN</td><td>Immunostar</td><td>Rabbit</td><td>Rat</td><td>1:500</td></tr></table>	<table><tr><td>Antibodies</td></tr><tr><td>CD34</td></tr><tr><td>5-HT</td></tr><tr><td>GFAP</td></tr><tr><td>APC</td></tr><tr><td>NeuN</td></tr></table>	<table><tr><td>Manufacturer</td><td>Source</td><td>Reactivity</td><td>Dilution</td></tr><tr><td>Sigma</td><td>Mouse</td><td>Rat</td><td>1:100</td></tr><tr><td>Immunostar</td><td>Rabbit</td><td>Rat</td><td>1:20,000</td></tr><tr><td>Millipore</td><td>Rabbit</td><td>Rat</td><td>1:50</td></tr><tr><td>Calbiochem</td><td>Mouse</td><td>Rat</td><td>1:200</td></tr><tr><td>Immunostar</td><td>Rabbit</td><td>Rat</td><td>1:500</td></tr></table>
1771cf213ddf45a3c88966e68cfb19ccd1efde7f0e2dc4c99e2281ac158e2994.png	simple	<table><tr><td>sTNF/TNFR1 signaling</td><td> </td></tr><tr><td>sTNF is necessary for the induction of autoimmune diseases [160]</td><td> </td></tr><tr><td>Association of TNF and TNFR1 polymorphisms with PD risk [14, 163]</td><td> </td></tr><tr><td>Association of TNFR1 polymorphism with MS risk [164]</td><td> </td></tr><tr><td>TNFR1 promotes neurodegeneration in retinal ischemia [165]</td><td> </td></tr><tr><td>TNFR1 mediates development of pain-induced depressive behavior [166] </td><td> </td></tr><tr><td>TNFR1 is essential for the development of MOG<sup>35–55</sup> induced EAE [167–169]</td><td> </td></tr><tr><td>Inhibition of TNFR1 signaling strongly ameliorates EAE development [169]</td><td> </td></tr><tr><td>Blocking of sTNF improves functional outcome in EAE [170, 171] </td><td> </td></tr><tr><td>Blocking sTNF attenuates neurodegeneration in AD and PD models [172–174]</td><td> </td></tr><tr><td>TNFR1 mediates direct apoptosis of neurons via caspase 8 [175]</td><td> </td></tr><tr><td>memTNF/TNFR2 signaling</td><td> </td></tr><tr><td>TNFR2<sup>−/−</sup> mice show exacerbated neurodegeneration in EAE model [167–169]</td><td> </td></tr><tr><td>TNFR2<sup>−/−</sup> mice show exacerbated neurodegeneration in retinal ischemia [165]</td><td> </td></tr><tr><td>TNFR2 promotes OPC proliferation and remyelination [176]</td><td> </td></tr><tr><td>TNFR2 protects neurons against glutamate-induced excitotoxicity [142, 143]</td><td> </td></tr><tr><td>memTNF dependent activation of NFkB is neuroprotective in EAE [171]</td><td> </td></tr><tr><td>TNFR2 rescues neurons from oxidative stress-induced cell death [144]</td><td> </td></tr><tr><td>TNFR2 promotes oligodendrocyte maturation [177]</td><td> </td></tr><tr><td>TNFR2 promotes oligodendrocyte proliferation and maturation [178]</td><td> </td></tr><tr><td>TNFR2 protects OPCs against oxidative stress [179]</td><td> </td></tr></table>	<table><tr><td>sTNF/TNFR1 signaling</td><td></td></tr><tr><td>sTNF is necessary for the induction of autoimmune diseases [160]</td><td></td></tr><tr><td>Association of TNF and TNFR1 polymorphisms with PD risk [14, 163]</td><td></td></tr><tr><td>Association of TNFR1 polymorphism with MS risk [164]</td><td></td></tr><tr><td>TNFR1 promotes neurodegeneration in retinal ischemia [165]</td><td></td></tr><tr><td>TNFR1 mediates development of pain-induced depressive behavior [166]</td><td></td></tr><tr><td>TNFR1 is essential for the development of MOG35–55 induced EAE [167–169]</td><td></td></tr><tr><td>Inhibition of TNFR1 signaling strongly ameliorates EAE development [169]</td><td></td></tr><tr><td>Blocking of sTNF improves functional outcome in EAE [170, 171]</td><td></td></tr><tr><td>Blocking sTNF attenuates neurodegeneration in AD and PD models [172–174]</td><td></td></tr><tr><td>TNFR1 mediates direct apoptosis of neurons via caspase 8 [175]</td><td></td></tr><tr><td>memTNF/TNFR2 signaling</td><td></td></tr><tr><td>TNFR2−/− mice show exacerbated neurodegeneration in EAE model [167–169]</td><td></td></tr><tr><td>TNFR2−/− mice show exacerbated neurodegeneration in retinal ischemia [165]</td><td></td></tr></table>	<table><tr><td>TNFR2 promotes OPC proliferation and remyelination [176]</td></tr><tr><td>TNFR2 protects neurons against glutamate-induced excitotoxicity [142, 143]</td></tr><tr><td>memTNF dependent activation of NFkB is neuroprotective in EAE [171]</td></tr><tr><td>TNFR2 rescues neurons from oxidative stress-induced cell death [144]</td></tr><tr><td>TNFR2 promotes oligodendrocyte maturation [177]</td></tr><tr><td>TNFR2 promotes oligodendrocyte proliferation and maturation [178]</td></tr><tr><td>TNFR2 protects OPCs against oxidative stress [179]</td></tr></table>
e70b22037fc754144623387958601c26a41bb363bc4a81d7ab7d6bce02ab03a0.png	simple	<table><tr><td>Structure</td><td>Damage Scale</td><td>Stiffness Adjustment</td><td>Flatfoot Stiffness (N/mm)</td></tr><tr><td>Superomedial spring</td><td>Stage IV</td><td>−7/8th</td><td>39</td></tr><tr><td>Inferomedial spring</td><td>Stage II</td><td>−3/8th</td><td>94</td></tr><tr><td>Talocalcaneal interosseus</td><td>Stage I</td><td>−1/8th</td><td>236</td></tr><tr><td>Plantar fascia</td><td>Stage I</td><td>−1/8th</td><td>175</td></tr><tr><td>Plantar metatarsocuneiform</td><td>Stage 0</td><td>None</td><td>90</td></tr><tr><td>Plantar naviculocuneiform</td><td>Stage 0</td><td>None</td><td>180</td></tr><tr><td>Long and short plantar</td><td>Stage 0</td><td>None</td><td>240</td></tr><tr><td>Deep deltoid</td><td>Stage 0</td><td>None</td><td>200</td></tr><tr><td>Anterior superficial deltoid</td><td>Stage I</td><td>−1/8th</td><td>70</td></tr><tr><td>Posterior superficial deltoid</td><td>Stage 0</td><td>None</td><td>117</td></tr></table>	<table><tr><td>Structure</td><td>Damage Scale</td><td>Stiffness Adjustment</td><td>Flatfoot Stiffness (N/mm)</td></tr><tr><td>Superomedial spring</td><td>Stage IV</td><td>−7/8th</td><td>39</td></tr><tr><td>Inferomedial spring</td><td>Stage II</td><td>−3/8th</td><td>94</td></tr><tr><td>Talocalcaneal interosseus</td><td>Stage I</td><td>−1/8th</td><td>236</td></tr><tr><td>Plantar fascia</td><td>Stage I</td><td>−1/8th</td><td>175</td></tr></table>	<table><tr><td>Plantar metatarsocuneiform</td><td>Stage 0</td><td>None</td><td>90</td></tr><tr><td>Plantar naviculocuneiform</td><td>Stage 0</td><td>None</td><td>180</td></tr><tr><td>Long and short plantar</td><td>Stage 0</td><td>None</td><td>240</td></tr><tr><td>Deep deltoid</td><td>Stage 0</td><td>None</td><td>200</td></tr><tr><td>Anterior superficial deltoid</td><td>Stage I</td><td>−1/8th</td><td>70</td></tr><tr><td>Posterior superficial deltoid</td><td>Stage 0</td><td>None</td><td>117</td></tr></table>
351638ac85eb5236645cefab448cc52cca40e9cd703b5a968b1ea42396b21cfe.png	simple	<table><tr><td>Usage</td><td>AAindex ID</td><td>Physicochemical properties</td></tr><tr><td>100%</td><td>MEEJ800102</td><td>Retention coefficient in HPLC, pH2.1</td></tr><tr><td>91%</td><td>WOLS870102</td><td>Principal property value z2</td></tr><tr><td>87%</td><td>CASG920101</td><td>Hydrophobicity scale from native proteins</td></tr><tr><td>84%</td><td>NAKH900110</td><td>Normalized composition of membrane proteins</td></tr><tr><td>81%</td><td>FASG760105</td><td>pK-C</td></tr><tr><td>79%</td><td>FAUJ880105</td><td>STERIMOL minimum width of the side chain</td></tr><tr><td>76%</td><td>CHAM830107</td><td>A parameter of charge transfer capability</td></tr><tr><td>61%</td><td>QIAN880127</td><td>Weights for coil at the window position of -6</td></tr><tr><td>59%</td><td>RACS820108</td><td>Average relative fractional occurrence in AR (i-1)</td></tr><tr><td>58%</td><td>DIGM050101</td><td>Hydrostatic pressure asymmetry index, PAI</td></tr><tr><td>56%</td><td>TANS770109</td><td>Normalized frequency of coil</td></tr></table>	<table><tr><td>Usage</td><td>AAindex ID</td><td>Physicochemical properties</td></tr><tr><td>100%</td><td>MEEJ800102</td><td>Retention coefficient in HPLC, pH2.1</td></tr><tr><td>91%</td><td>WOLS870102</td><td>Principal property value z2</td></tr><tr><td>87%</td><td>CASG920101</td><td>Hydrophobicity scale from native proteins</td></tr><tr><td>84%</td><td>NAKH900110</td><td>Normalized composition of membrane proteins</td></tr><tr><td>81%</td><td>FASG760105</td><td>pK-C</td></tr><tr><td>79%</td><td>FAUJ880105</td><td>STERIMOL minimum width of the side chain</td></tr><tr><td>76%</td><td>CHAM830107</td><td>A parameter of charge transfer capability</td></tr><tr><td>61%</td><td>QIAN880127</td><td>Weights for coil at the window position of -6</td></tr><tr><td>59%</td><td>RACS820108</td><td>Average relative fractional occurrence in AR (i-1)</td></tr><tr><td>58%</td><td>DIGM050101</td><td>Hydrostatic pressure asymmetry index, PAI</td></tr></table>	<table><tr><td>Usage</td><td>AAindex ID</td><td>Physicochemical properties</td></tr><tr><td>56%</td><td>TANS770109</td><td>Normalized frequency of coil</td></tr></table>
330c5c8fbd6d56041b50591f075f53162948f87c5711fcbd8a80c06d3a490945.png	complex	<table><tr><td></td><td>All patients (<i>n</i> = 1119)</td><td>LBBB (<i>n</i> = 221)</td><td>RBBB (<i>n</i> = 82)</td><td>IVCD (<i>n</i> = 67)</td><td>Narrow QRS (<i>n</i> = 749)</td><td><i>P</i> value</td></tr><tr><td>Age (years)</td><td>51.1 ± 14.7</td><td>57.2 ± 12.0</td><td>53.1 ± 14.7</td><td>52.3 ± 14.5</td><td>48.9 ± 14.9</td><td><0.001<sup>a</sup></td></tr><tr><td>Female gender, n (%)</td><td>298(26.6)</td><td>89(40.3)</td><td>16(19.5)</td><td>15(22.4)</td><td>178(23.8)</td><td><0.001</td></tr><tr><td colspan="7">History</td></tr><tr><td> Disease duration (years)</td><td>2(0.5–6)</td><td>4(1–9)</td><td>4(1–8)</td><td>3(1.5–6)</td><td>2(0.35–5)</td><td>0.001</td></tr><tr><td> Essential hypertension, n (%)</td><td>294(26.3)</td><td>73(33.0)</td><td>15(18.3)</td><td>15(22.4)</td><td>191(25.5)</td><td>0.034</td></tr><tr><td> Diabetes mellitus, n (%)</td><td>160(14.3)</td><td>24(10.9)</td><td>15(18.3)</td><td>6(9.0)</td><td>115(15.4)</td><td>0.142</td></tr><tr><td> Atrial fibrillation, n (%)</td><td>257(23.0)</td><td>29(13.1)</td><td>20(24.4)</td><td>11(16.4)</td><td>197(26.3)</td><td><0.001</td></tr><tr><td> Smoker, n (%)</td><td>517(46.2)</td><td>93(42.1)</td><td>33(40.2)</td><td>31(46.3)</td><td>360(48.1)</td><td>0.293</td></tr><tr><td> Drinker, n (%)</td><td>363(32.4)</td><td>59(26.7)</td><td>28(34.1)</td><td>22(32.8)</td><td>254(33.9)</td><td>0.243</td></tr><tr><td> NYHA class III and IV<sup>c</sup>, n (%)</td><td>817(73.0)</td><td>162(73.3)</td><td>60(73.2)</td><td>54(80.6)</td><td>541(72.2)</td><td>0.532</td></tr><tr><td colspan="7">Admission vital signs</td></tr><tr><td> SBP (mm Hg)</td><td>113.0 ± 17.7</td><td>114.6 ± 17.3</td><td>110.2 ± 18.8</td><td>111.7 ± 19.8</td><td>113.0 ± 17.4</td><td>0.242</td></tr><tr><td> DBP(mm Hg)</td><td>72.5 ± 12.6</td><td>71.8 ± 12.4</td><td>71.8 ± 11.1</td><td>69.3 ± 12.4</td><td>73.0 + 12.8</td><td>0.099</td></tr><tr><td> Heart rate, beat/min</td><td>80.9 ± 17.4</td><td>78.3 ± 15.9</td><td>79.6 ± 15.5</td><td>78.6 ± 14.4</td><td>82.0 ± 18.2</td><td>0.023</td></tr><tr><td colspan="7">Laboratory values at admission<sup>b</sup></td></tr><tr><td> TB (mmol/L)</td><td>26.2 ± 19.6</td><td>24.9 ± 19.1</td><td>25.3 ± 16.0</td><td>34.8 ± 26.7</td><td>26.0 ± 19.3</td><td>0.004</td></tr><tr><td> DB (mmol/L)</td><td>3.7(2.5–6.5)</td><td>3.2(2.15–6.05)</td><td>3.5(2.7–7.4)</td><td>4.9(3.2–9.2)</td><td>3.7(2.5–6.485)</td><td>0.003</td></tr><tr><td> Glucose (mmol/L)</td><td>5.62 ± 1.85</td><td>5.86 ± 1.94</td><td>5.50 ± 1.52</td><td>5.34 ± 1.44</td><td>5.59 ± 1.89</td><td>0.150</td></tr><tr><td> Triglyceride (mmol/L)</td><td>1.57 ± 1.02</td><td>1.63 ± 0.99</td><td>1.58 ± 0.94</td><td>1.38 ± 0.70</td><td>1.56 ± 1.06</td><td>0.410</td></tr><tr><td> Total cholesterol (mmol/L)</td><td>4.61 ± 1.13</td><td>4.75 ± 1.12</td><td>4.52 ± 0.98</td><td>4.39 ± 1.23</td><td>4.59 ± 1.14</td><td>0.125</td></tr><tr><td> Creatinine (μmol/L)</td><td>92.8 ± 35.2</td><td>91.0 ± 26.4</td><td>94.9 ± 25.9</td><td>97.9 ± 40.7</td><td>92.6 ± 37.8</td><td>0.526</td></tr><tr><td> BUN (μmol/L)</td><td>7.95 ± 3.97</td><td>7.88 ± 2.67</td><td>8.04 ± 2.69</td><td>8.89 ± 4.68</td><td>7.88 ± 4.32</td><td>0.262</td></tr><tr><td> CK-MB (IU/L)</td><td>13.5 ± 7.76</td><td>13.1 ± 6.77</td><td>12.0 ± 6.70</td><td>13.7 ± 7.59</td><td>13.8 ± 8.14</td><td>0.229</td></tr><tr><td> NT- Pro- BNP (fmol/mL)</td><td>2010.3 ± 1567.5</td><td>1998.0 ± 1595.8</td><td>2170.5 ± 1679.8</td><td>2358.4 ± 1638.4</td><td>1962.4 ± 1538.0</td><td>0.315</td></tr><tr><td colspan="7">Electrocardiogram data</td></tr><tr><td> QRS duration (ms)</td><td>119.6 ± 30.9</td><td>156.0 ± 24.4</td><td>153.3 ± 24.9</td><td>137.1 ± 23.1</td><td>103.6 ± 18.2</td><td><0.001</td></tr><tr><td> QT (ms)</td><td>405.7 ± 54.2</td><td>434.4 ± 50.6</td><td>429.1 ± 51.1</td><td>421.3 ± 38.7</td><td>393.2 ± 52.4</td><td><0.001</td></tr><tr><td> P (ms)</td><td>107.5 ± 21.6</td><td>102.7 ± 22.6</td><td>107.5 ± 23.6</td><td>108.2 ± 25.1</td><td>109.3 ± 20.3</td><td>0.005</td></tr><tr><td> PR (ms)</td><td>182.8 ± 32.9</td><td>184.9 ± 33.1</td><td>192.3 ± 42.0</td><td>193.6 ± 34.7</td><td>179.7 ± 30.7</td><td>0.001</td></tr><tr><td colspan="7">Echocardiography data</td></tr><tr><td> LV (mm)</td><td>68.0 ± 9.3</td><td>71.4 ± 11.4</td><td>68.7 ± 8.3</td><td>70.9 ± 13.1</td><td>66.7 ± 8.0</td><td><0.001</td></tr><tr><td> LVEF (%)</td><td>31.9 ± 8.4</td><td>31.0 ± 8.2</td><td>31.8 ± 7.3</td><td>30.5 ± 9.0</td><td>32.3 ± 8.5</td><td>0.142</td></tr><tr><td> RV (mm)</td><td>23.6 ± 5.4</td><td>22.0 ± 5.0</td><td>24.1 ± 5.6</td><td>24.5 ± 5.5</td><td>24.0 ± 5.4</td><td><0.001</td></tr><tr><td> LA (mm)</td><td>43.9 ± 7.7</td><td>43.1 ± 7.9</td><td>45.8 ± 8.4</td><td>46.6 ± 8.9</td><td>43.7 ± 7.5</td><td>0.002</td></tr><tr><td> PASP (>40 mmHg), n (%)</td><td>203(18.1)</td><td>35(15.8)</td><td>24(29.3)</td><td>15(22.4)</td><td>129(17.2)</td><td>0.031</td></tr><tr><td colspan="7">Medicine during admission</td></tr><tr><td> Diuretics, n (%)</td><td>1059(94.6)</td><td>205(92.8)</td><td>76(92.7)</td><td>63(94.0)</td><td>715(95.5)</td><td>0.362</td></tr><tr><td> ACEI/ARB, n (%)</td><td>951(85.0)</td><td>182(82.4)</td><td>70(85.4)</td><td>54(80.6)</td><td>645(86.1)</td><td>0.396</td></tr><tr><td> Beta-blockers, n (%)</td><td>1017(90.9)</td><td>195(88.2)</td><td>69(84.1)</td><td>56(83.6)</td><td>697(93.1)</td><td>0.002</td></tr><tr><td> Digoxin, n (%)</td><td>903(80.7)</td><td>168(76.0)</td><td>66(80.5)</td><td>59(88.1)</td><td>610(81.4)</td><td>0.127</td></tr><tr><td> Aspirin/anticoagulants n (%)</td><td>721(64.4)</td><td>131(59.3)</td><td>52(63.4)</td><td>34(50.7)</td><td>504(67.3)</td><td>0.013</td></tr><tr><td> Spironolactone, n (%)</td><td>1019(91.1)</td><td>191(86.4)</td><td>73(89.0)</td><td>57(85.1)</td><td>698(93.2)</td><td>0.004</td></tr></table>	<table><tr><td></td><td>All patients (n = 1119)</td><td>LBBB (n = 221)</td><td>RBBB (n = 82)</td><td>IVCD (n = 67)</td><td>Narrow QRS (n = 749)</td><td>P value</td></tr><tr><td>Age (years)</td><td>51.1 ± 14.7</td><td>57.2 ± 12.0</td><td>53.1 ± 14.7</td><td>52.3 ± 14.5</td><td>48.9 ± 14.9</td><td><0.001a</td></tr><tr><td>Female gender, n (%)</td><td>298(26.6)</td><td>89(40.3)</td><td>16(19.5)</td><td>15(22.4)</td><td>178(23.8)</td><td><0.001</td></tr><tr><td colspan="7">History</td></tr></table>	<table><tr><td>Disease duration (years)</td><td>2(0.5–6)</td><td>4(1–9)</td><td>4(1–8)</td><td>3(1.5–6)</td><td>2(0.35–5)</td><td>0.001</td></tr><tr><td>Essential hypertension, n (%)</td><td>294(26.3)</td><td>73(33.0)</td><td>15(18.3)</td><td>15(22.4)</td><td>191(25.5)</td><td>0.034</td></tr><tr><td>Diabetes mellitus, n (%)</td><td>160(14.3)</td><td>24(10.9)</td><td>15(18.3)</td><td>6(9.0)</td><td>115(15.4)</td><td>0.142</td></tr><tr><td>Atrial fibrillation, n (%)</td><td>257(23.0)</td><td>29(13.1)</td><td>20(24.4)</td><td>11(16.4)</td><td>197(26.3)</td><td><0.001</td></tr><tr><td>Smoker, n (%)</td><td>517(46.2)</td><td>93(42.1)</td><td>33(40.2)</td><td>31(46.3)</td><td>360(48.1)</td><td>0.293</td></tr><tr><td>Drinker, n (%)</td><td>363(32.4)</td><td>59(26.7)</td><td>28(34.1)</td><td>22(32.8)</td><td>254(33.9)</td><td>0.243</td></tr><tr><td>NYHA class III and IVc, n (%)</td><td>817(73.0)</td><td>162(73.3)</td><td>60(73.2)</td><td>54(80.6)</td><td>541(72.2)</td><td>0.532</td></tr><tr><td colspan="7">Admission vital signs</td></tr><tr><td>SBP (mm Hg)</td><td>113.0 ± 17.7</td><td>114.6 ± 17.3</td><td>110.2 ± 18.8</td><td>111.7 ± 19.8</td><td>113.0 ± 17.4</td><td>0.242</td></tr><tr><td>DBP(mm Hg)</td><td>72.5 ± 12.6</td><td>71.8 ± 12.4</td><td>71.8 ± 11.1</td><td>69.3 ± 12.4</td><td>73.0 + 12.8</td><td>0.099</td></tr><tr><td>Heart rate, beat/min</td><td>80.9 ± 17.4</td><td>78.3 ± 15.9</td><td>79.6 ± 15.5</td><td>78.6 ± 14.4</td><td>82.0 ± 18.2</td><td>0.023</td></tr><tr><td colspan="7">Laboratory values at admissionb</td></tr><tr><td>TB (mmol/L)</td><td>26.2 ± 19.6</td><td>24.9 ± 19.1</td><td>25.3 ± 16.0</td><td>34.8 ± 26.7</td><td>26.0 ± 19.3</td><td>0.004</td></tr><tr><td>DB (mmol/L)</td><td>3.7(2.5–6.5)</td><td>3.2(2.15–6.05)</td><td>3.5(2.7–7.4)</td><td>4.9(3.2–9.2)</td><td>3.7(2.5–6.485)</td><td>0.003</td></tr><tr><td>Glucose (mmol/L)</td><td>5.62 ± 1.85</td><td>5.86 ± 1.94</td><td>5.50 ± 1.52</td><td>5.34 ± 1.44</td><td>5.59 ± 1.89</td><td>0.150</td></tr><tr><td>Triglyceride (mmol/L)</td><td>1.57 ± 1.02</td><td>1.63 ± 0.99</td><td>1.58 ± 0.94</td><td>1.38 ± 0.70</td><td>1.56 ± 1.06</td><td>0.410</td></tr><tr><td>Total cholesterol (mmol/L)</td><td>4.61 ± 1.13</td><td>4.75 ± 1.12</td><td>4.52 ± 0.98</td><td>4.39 ± 1.23</td><td>4.59 ± 1.14</td><td>0.125</td></tr><tr><td>Creatinine (μmol/L)</td><td>92.8 ± 35.2</td><td>91.0 ± 26.4</td><td>94.9 ± 25.9</td><td>97.9 ± 40.7</td><td>92.6 ± 37.8</td><td>0.526</td></tr><tr><td>BUN (μmol/L)</td><td>7.95 ± 3.97</td><td>7.88 ± 2.67</td><td>8.04 ± 2.69</td><td>8.89 ± 4.68</td><td>7.88 ± 4.32</td><td>0.262</td></tr><tr><td>CK-MB (IU/L)</td><td>13.5 ± 7.76</td><td>13.1 ± 6.77</td><td>12.0 ± 6.70</td><td>13.7 ± 7.59</td><td>13.8 ± 8.14</td><td>0.229</td></tr><tr><td>NT- Pro- BNP (fmol/mL)</td><td>2010.3 ± 1567.5</td><td>1998.0 ± 1595.8</td><td>2170.5 ± 1679.8</td><td>2358.4 ± 1638.4</td><td>1962.4 ± 1538.0</td><td>0.315</td></tr><tr><td colspan="7">Electrocardiogram data</td></tr><tr><td>QRS duration (ms)</td><td>119.6 ± 30.9</td><td>156.0 ± 24.4</td><td>153.3 ± 24.9</td><td>137.1 ± 23.1</td><td>103.6 ± 18.2</td><td><0.001</td></tr><tr><td>QT (ms)</td><td>405.7 ± 54.2</td><td>434.4 ± 50.6</td><td>429.1 ± 51.1</td><td>421.3 ± 38.7</td><td>393.2 ± 52.4</td><td><0.001</td></tr><tr><td>P (ms)</td><td>107.5 ± 21.6</td><td>102.7 ± 22.6</td><td>107.5 ± 23.6</td><td>108.2 ± 25.1</td><td>109.3 ± 20.3</td><td>0.005</td></tr><tr><td>PR (ms)</td><td>182.8 ± 32.9</td><td>184.9 ± 33.1</td><td>192.3 ± 42.0</td><td>193.6 ± 34.7</td><td>179.7 ± 30.7</td><td>0.001</td></tr><tr><td colspan="7">Echocardiography data</td></tr><tr><td>LV (mm)</td><td>68.0 ± 9.3</td><td>71.4 ± 11.4</td><td>68.7 ± 8.3</td><td>70.9 ± 13.1</td><td>66.7 ± 8.0</td><td><0.001</td></tr><tr><td>LVEF (%)</td><td>31.9 ± 8.4</td><td>31.0 ± 8.2</td><td>31.8 ± 7.3</td><td>30.5 ± 9.0</td><td>32.3 ± 8.5</td><td>0.142</td></tr><tr><td>RV (mm)</td><td>23.6 ± 5.4</td><td>22.0 ± 5.0</td><td>24.1 ± 5.6</td><td>24.5 ± 5.5</td><td>24.0 ± 5.4</td><td><0.001</td></tr><tr><td>LA (mm)</td><td>43.9 ± 7.7</td><td>43.1 ± 7.9</td><td>45.8 ± 8.4</td><td>46.6 ± 8.9</td><td>43.7 ± 7.5</td><td>0.002</td></tr><tr><td>PASP (>40 mmHg), n (%)</td><td>203(18.1)</td><td>35(15.8)</td><td>24(29.3)</td><td>15(22.4)</td><td>129(17.2)</td><td>0.031</td></tr><tr><td colspan="7">Medicine during admission</td></tr><tr><td>Diuretics, n (%)</td><td>1059(94.6)</td><td>205(92.8)</td><td>76(92.7)</td><td>63(94.0)</td><td>715(95.5)</td><td>0.362</td></tr><tr><td>ACEI/ARB, n (%)</td><td>951(85.0)</td><td>182(82.4)</td><td>70(85.4)</td><td>54(80.6)</td><td>645(86.1)</td><td>0.396</td></tr><tr><td>Beta-blockers, n (%)</td><td>1017(90.9)</td><td>195(88.2)</td><td>69(84.1)</td><td>56(83.6)</td><td>697(93.1)</td><td>0.002</td></tr><tr><td>Digoxin, n (%)</td><td>903(80.7)</td><td>168(76.0)</td><td>66(80.5)</td><td>59(88.1)</td><td>610(81.4)</td><td>0.127</td></tr><tr><td>Aspirin/anticoagulants n (%)</td><td>721(64.4)</td><td>131(59.3)</td><td>52(63.4)</td><td>34(50.7)</td><td>504(67.3)</td><td>0.013</td></tr><tr><td>Spironolactone, n (%)</td><td>1019(91.1)</td><td>191(86.4)</td><td>73(89.0)</td><td>57(85.1)</td><td>698(93.2)</td><td>0.004</td></tr></table>
8e413acbb521002dcc117eb0865f50563dccd173d9d111af80b6e2563c89a230.png	complex	<table><tr><td rowspan="2">Treatment groups</td><td colspan="2">Continuous exposure profile</td><td colspan="2">Cross-over exposure profile</td></tr><tr><td>CC</td><td>TT</td><td>CT</td><td>TC</td></tr><tr><td>CC</td><td></td><td>42</td><td>53</td><td>42</td></tr><tr><td>TT</td><td>42</td><td></td><td>36</td><td>31</td></tr><tr><td>CT</td><td>53</td><td>36</td><td></td><td>39</td></tr><tr><td>TC</td><td>42</td><td>31</td><td>39</td><td></td></tr></table>	<table><tr><td rowspan="2">Treatment groups</td><td colspan="2">Continuous exposure profile</td></tr><tr><td>CC</td><td>TT</td></tr><tr><td>CC</td><td></td><td>42</td></tr><tr><td>TT</td><td>42</td><td></td></tr><tr><td>CT</td><td>53</td><td>36</td></tr><tr><td>TC</td><td>42</td><td>31</td></tr></table>	<table><tr><td colspan="2">Cross-over exposure profile</td></tr><tr><td>CT</td><td>TC</td></tr><tr><td>53</td><td>42</td></tr><tr><td>36</td><td>31</td></tr><tr><td></td><td>39</td></tr><tr><td>39</td><td></td></tr></table>
477427e14544cf8b4d86bcb90d99578468231858031f13e6dec36f9f5185b5a9.png	simple	<table><tr><td><i>XXY ID</i></td><td><i>Sequence (XX_Y)</i></td><td><i>N Species</i></td><td><i>freq (%)</i></td><td><i>N changes*</i></td></tr><tr><td>1</td><td>AAaTGAAGAAAAcGAAGA_ATGAAGA</td><td>2</td><td>2.11</td><td>2</td></tr><tr><td>2</td><td>AAaTGAAGAAAATGAAGA_ATGAAGA</td><td>27</td><td>28.42</td><td>1</td></tr><tr><td>3</td><td>AAaTGAAGAAAATGAAGA_ATGAgGA</td><td>2</td><td>2.11</td><td>2</td></tr><tr><td>4</td><td>AAaTGAAGAcAATGAAGA_ATGAAGA</td><td>3</td><td>3.16</td><td>2</td></tr><tr><td>5</td><td>AAaTGAgGAAAATGAAGA_ATGAAGA</td><td>1</td><td>1.05</td><td>2</td></tr><tr><td>6</td><td>AACaGAAGAAAAcGAAGA_ATGAAGA</td><td>2</td><td>2.11</td><td>2</td></tr><tr><td>7</td><td>AACcGAAGAAAAcGAAGA_ATGAAGA</td><td>1</td><td>1.05</td><td>2</td></tr><tr><td>8</td><td>AACTGAAGAAAAcGAAGA_ATGAAGA</td><td>11</td><td>11.58</td><td>1</td></tr><tr><td>9</td><td>AACTGAAGAAAATGAAGA_AcGAAGA</td><td>1</td><td>1.05</td><td>1</td></tr><tr><td>10</td><td>AACTGAAGAAAATGAAGA_ATGAAGA</td><td>40</td><td>42.11</td><td>0</td></tr><tr><td>11</td><td>AACTGAAGAcAATGAAGA_ATGAAGA</td><td>3</td><td>3.16</td><td>1</td></tr><tr><td>12</td><td>cAgTGAAGAAAATGAAGA_ATGAAGA</td><td>1</td><td>1.05</td><td>2</td></tr><tr><td>13</td><td>cAgTGAAGAtAAcGAAGA_ATGAAGA</td><td>1</td><td>1.05</td><td>4</td></tr></table>	<table><tr><td>XXY ID</td><td>Sequence (XX_Y)</td><td>N Species</td><td>freq (%)</td><td>N changes*</td></tr><tr><td>1</td><td>AAaTGAAGAAAAcGAAGA_ATGAAGA</td><td>2</td><td>2.11</td><td>2</td></tr><tr><td>2</td><td>AAaTGAAGAAAATGAAGA_ATGAAGA</td><td>27</td><td>28.42</td><td>1</td></tr><tr><td>3</td><td>AAaTGAAGAAAATGAAGA_ATGAgGA</td><td>2</td><td>2.11</td><td>2</td></tr><tr><td>4</td><td>AAaTGAAGAcAATGAAGA_ATGAAGA</td><td>3</td><td>3.16</td><td>2</td></tr><tr><td>5</td><td>AAaTGAgGAAAATGAAGA_ATGAAGA</td><td>1</td><td>1.05</td><td>2</td></tr><tr><td>6</td><td>AACaGAAGAAAAcGAAGA_ATGAAGA</td><td>2</td><td>2.11</td><td>2</td></tr><tr><td>7</td><td>AACcGAAGAAAAcGAAGA_ATGAAGA</td><td>1</td><td>1.05</td><td>2</td></tr><tr><td>8</td><td>AACTGAAGAAAAcGAAGA_ATGAAGA</td><td>11</td><td>11.58</td><td>1</td></tr><tr><td>9</td><td>AACTGAAGAAAATGAAGA_AcGAAGA</td><td>1</td><td>1.05</td><td>1</td></tr></table>	<table><tr><td>XXY ID</td><td>Sequence (XX_Y)</td><td>N Species</td><td>freq (%)</td><td>N changes*</td></tr><tr><td>10</td><td>AACTGAAGAAAATGAAGA_ATGAAGA</td><td>40</td><td>42.11</td><td>0</td></tr><tr><td>11</td><td>AACTGAAGAcAATGAAGA_ATGAAGA</td><td>3</td><td>3.16</td><td>1</td></tr><tr><td>12</td><td>cAgTGAAGAAAATGAAGA_ATGAAGA</td><td>1</td><td>1.05</td><td>2</td></tr><tr><td>13</td><td>cAgTGAAGAtAAcGAAGA_ATGAAGA</td><td>1</td><td>1.05</td><td>4</td></tr></table>
3a1a9be4682b1b0020d79ee4438a467ef50ca77cc37d619a3970c6b1036186a5.png	simple	<table><tr><td>Participants</td><td>Nationality</td><td>Sex</td><td>Age category</td><td>Migratory status</td><td>Health complaints</td><td>Received treatments while undocumented migrant in Denmark</td></tr><tr><td>P01</td><td>Bangladeshi</td><td>Male</td><td>31-40</td><td>Failed asylum seeker</td><td>Dental problems, mental health problems</td><td>None</td></tr><tr><td>P02</td><td>Bangladeshi</td><td>Male</td><td>31-40</td><td>Failed asylum seeker</td><td>Superficial wounds after assault, asthma</td><td>Prescription for medication fromgeneral practitioner</td></tr><tr><td>P03</td><td>Bangladeshi</td><td>Male</td><td>21-30</td><td>Failed asylum seeker</td><td>Psoriasis, mental health problems</td><td>Treatment for psoriasis throughinformal networks of healthcare professionals and at a hospitaldermatology department</td></tr><tr><td>P04</td><td>Bangladeshi</td><td>Male</td><td>41-50</td><td>Failed asylum seeker</td><td>Leg fracture, mental health problems, cancer suspicion</td><td>Treatment for a leg fracture at hospital ER, check-up athospital oncology department</td></tr><tr><td>P05</td><td>Indian</td><td>Male</td><td>41-50</td><td>Failed asylum seeker</td><td>Diabetes, high blood pressure, heart disease, mental health problems</td><td>Treatment for depressionthrough informal networks ofhealthcare professionals. Medical supplies throughpersonal networks</td></tr><tr><td>P06</td><td>Indian</td><td>Male</td><td>31-40</td><td>Overstayer</td><td>Dental problems, ulcer, sprained foot,mental health problems</td><td>Treatment for a sprained foot at hospital ER</td></tr><tr><td>P07</td><td>Nepali</td><td>Male</td><td>21-30</td><td>Overstayer</td><td>None</td><td>None</td></tr><tr><td>P08</td><td>Nepali</td><td>Male</td><td>31-40</td><td>Overstayer</td><td>Dental problems, mental health problems</td><td>None</td></tr><tr><td>P09</td><td>Nepali</td><td>Male</td><td>21-30</td><td>Overstayer</td><td>Sprained hand, skin allergy</td><td>None</td></tr><tr><td>P10</td><td>Nepali</td><td>Male</td><td>21-30</td><td>Overstayer</td><td>Mental health problems</td><td>None</td></tr></table>	<table><tr><td>Participants</td><td>Nationality</td><td>Sex</td><td>Age category</td><td>Migratory status</td><td>Health complaints</td><td>Received treatments while undocumented migrant in Denmark</td></tr><tr><td>P01</td><td>Bangladeshi</td><td>Male</td><td>31-40</td><td>Failed asylum seeker</td><td>Dental problems, mental health problems</td><td>None</td></tr><tr><td>P02</td><td>Bangladeshi</td><td>Male</td><td>31-40</td><td>Failed asylum seeker</td><td>Superficial wounds after assault, asthma</td><td>Prescription for medication fromgeneral practitioner</td></tr><tr><td>P03</td><td>Bangladeshi</td><td>Male</td><td>21-30</td><td>Failed asylum seeker</td><td>Psoriasis, mental health problems</td><td>Treatment for psoriasis throughinformal networks of healthcare professionals and at a hospitaldermatology department</td></tr><tr><td>P04</td><td>Bangladeshi</td><td>Male</td><td>41-50</td><td>Failed asylum seeker</td><td>Leg fracture, mental health problems, cancer suspicion</td><td>Treatment for a leg fracture at hospital ER, check-up athospital oncology department</td></tr><tr><td>P05</td><td>Indian</td><td>Male</td><td>41-50</td><td>Failed asylum seeker</td><td>Diabetes, high blood pressure, heart disease, mental health problems</td><td>Treatment for depressionthrough informal networks ofhealthcare professionals. Medical supplies throughpersonal networks</td></tr><tr><td>P06</td><td>Indian</td><td>Male</td><td>31-40</td><td>Overstayer</td><td>Dental problems, ulcer, sprained foot,mental health problems</td><td>Treatment for a sprained foot at hospital ER</td></tr></table>	<table><tr><td>Participants</td><td>Nationality</td><td>Sex</td><td>Age category</td><td>Migratory status</td><td>Health complaints</td><td>Received treatments while undocumented migrant in Denmark</td></tr><tr><td>P07</td><td>Nepali</td><td>Male</td><td>21-30</td><td>Overstayer</td><td>None</td><td>None</td></tr><tr><td>P08</td><td>Nepali</td><td>Male</td><td>31-40</td><td>Overstayer</td><td>Dental problems, mental health problems</td><td>None</td></tr><tr><td>P09</td><td>Nepali</td><td>Male</td><td>21-30</td><td>Overstayer</td><td>Sprained hand, skin allergy</td><td>None</td></tr><tr><td>P10</td><td>Nepali</td><td>Male</td><td>21-30</td><td>Overstayer</td><td>Mental health problems</td><td>None</td></tr></table>
587806a7e81461905248c0ba60223492a95de4058bf68fd9ed3ca2d21c6cd781.png	simple	<table><tr><td></td><td>Linear model</td><td>Ordered probit model</td></tr><tr><td>Men 15-44</td><td></td><td></td></tr><tr><td>Gap in VAS</td><td>0.196</td><td>0.186</td></tr><tr><td>Prevalence effect</td><td>-0.082</td><td>-0.102</td></tr><tr><td>Severity effect</td><td>0.239</td><td>0.030</td></tr><tr><td>Interaction</td><td>0.038</td><td>-0.012</td></tr><tr><td>Women 65-74</td><td></td><td></td></tr><tr><td>Difference</td><td>-0.902</td><td>-0.664</td></tr><tr><td>Prevalence effect</td><td>-0.575</td><td>-0.699</td></tr><tr><td>Severity effect</td><td>0.305</td><td>0.372</td></tr><tr><td>Interaction</td><td>-0.632</td><td>-0.646</td></tr><tr><td>Women 75 & more</td><td></td><td></td></tr><tr><td>Difference</td><td>-1.205</td><td>-1.182</td></tr><tr><td>Prevalence effect</td><td>-1.117</td><td>-1.189</td></tr><tr><td>Severity effect</td><td>-0.839</td><td>-0.088</td></tr><tr><td>Interaction</td><td>-0.049</td><td>-0.905</td></tr></table>	<table><tr><td></td><td>Linear model</td><td>Ordered probit model</td></tr><tr><td>Men 15-44</td><td></td><td></td></tr><tr><td>Gap in VAS</td><td>0.196</td><td>0.186</td></tr><tr><td>Prevalence effect</td><td>-0.082</td><td>-0.102</td></tr><tr><td>Severity effect</td><td>0.239</td><td>0.030</td></tr><tr><td>Interaction</td><td>0.038</td><td>-0.012</td></tr><tr><td>Wo</td><td></td><td></td></tr></table>	<table><tr><td>men 65-74</td><td></td><td></td></tr><tr><td>Difference</td><td>-0.902</td><td>-0.664</td></tr><tr><td>Prevalence effect</td><td>-0.575</td><td>-0.699</td></tr><tr><td>Severity effect</td><td>0.305</td><td>0.372</td></tr><tr><td>Interaction</td><td>-0.632</td><td>-0.646</td></tr><tr><td>Women 75 & more</td><td></td><td></td></tr><tr><td>Difference</td><td>-1.205</td><td>-1.182</td></tr><tr><td>Prevalence effect</td><td>-1.117</td><td>-1.189</td></tr><tr><td>Severity effect</td><td>-0.839</td><td>-0.088</td></tr><tr><td>Interaction</td><td>-0.049</td><td>-0.905</td></tr></table>
0d4bb2438e392ba0f24139e02426d9aae73137f00248a4389b944f1f4eea919b.png	complex	<table><tr><td>Study</td><td>Criteria used for prophylaxis</td><td>Antifungal used for prophylaxis</td><td>Invasive candidiasis</td><td>Commentary</td></tr><tr><td colspan="5">Positive prophylactic studies</td></tr><tr><td>Slotman et al.1987 [77]</td><td>Abdominal surgery+ ≥ 3 risk factors</td><td>Ketoconazole 200 mg/d POPlacebo</td><td>0/27 (0%)5/30 (17%)<sup>†</sup></td><td>Costs: $4,800 vs. $10,000<sup>†</sup>LOS: 6.0 vs. 12.5 days<sup>†</sup></td></tr><tr><td>Savino et al.1992 [78]</td><td>Surgical patients+ hypermetabolism</td><td>Nystatin/norfloxacin POPlacebo</td><td>6/25 (24%)13/21 (62%)<sup>‡</sup></td><td>NI per patient:0.9 vs. 2.0<sup>†</sup></td></tr><tr><td>Desai et al.1992 [79]</td><td>Severely burned patients</td><td>Nystatin/polymyxin SDDNo prophylaxis</td><td>34/1042 (3.3%)0/1439 (0%)<sup>†</sup></td><td>Superficial infections:59 (21%) vs. 22 (10%)<sup>†</sup></td></tr><tr><td>Eggimann et al.1999 [39] </td><td>Abdominal surgery+ tertiary peritonitis</td><td>Fluconazole 400 mg/d IVPlacebo</td><td>1/23 (9%)7/20 (35%)<sup>‡</sup></td><td>Candida peritonitis1 (4%) vs. 7 (35%)<sup>†</sup></td></tr><tr><td>Pelz et al.2001 [43] </td><td>Surgical patients+ LOS > 3 days</td><td>Fluconazole 400 mg/d POPlacebo</td><td>11/130 (8%)20/130 (15%)<sup>†</sup></td><td>> 75% colonized at randomization</td></tr><tr><td>Garbino et al.2002 [42] </td><td>Mechanically ventilated > 96 h</td><td>Fluconazole 100 mg PO + SDDPlacebo + SDD</td><td>4/103 (4%)10/101 (10%)<sup>‡</sup></td><td>Candidemia: 9 vs. 1(RR 0.1; CI 0.02-0.74)<sup>†</sup></td></tr><tr><td>Jacobs et al.2003 [80] </td><td>ICU+ septic shock</td><td>Fluconazole 200 mg IV/dPlacebo</td><td>0/32 (0%)1/39 (3%)<sup>‡</sup></td><td>Mortality significantly reduced in peritonitis</td></tr><tr><td>He et al.2003 [81]</td><td>Severe acute pancreatitis</td><td>Fluconazole 100 mg IV/dPlacebo</td><td>2/22 (9%)<sup>†</sup>7/23 (30%)<sup>†</sup></td><td>Mortality 2/2 (100%)Mortality 3/7 (43%)</td></tr><tr><td colspan="5">Negative prophylactic studies</td></tr><tr><td>Savino et al.1994 [78]</td><td>Surgical patients+ LOS > 2 days</td><td>Nystatin 2 × 10<sup>6 </sup>4 ×/d POKetoconazole 200 mg/d POClotrimazole 10 mg 3 ×/d PONo prophylaxis</td><td>5/75 (7%)1/65 (2%)<sup>‡</sup>1/80 (1%)<sup>‡</sup>2/72 (3%)<sup>‡</sup></td><td></td></tr><tr><td>Ables et al.2000 [82]</td><td>Surgical patients+ LOS > 2 days + other risk factors</td><td>Fluconazole 3 mg/kg 3 ×/wPlacebo</td><td>8/60 (13%)11/59 (19%)<sup>‡</sup></td><td></td></tr><tr><td>Sandven et al.2002 [40]</td><td>Surgery for peritonitis</td><td>Fluconazole 400 mg/d IVPlacebo</td><td>--</td><td>Mortality rates NS4/53 (8%) vs. 8/56 (14%)</td></tr><tr><td>Schuster et al.2008 [83]*</td><td>ICU ≥ 4 d+ Fever > 4 d under broad-spectrum antibiotics+ APACHE II ≥ 16</td><td>Fluconazole 400 mg/d IVPlacebo</td><td>6/122 (5%)11/127 (9%)<sup>‡</sup></td><td></td></tr></table>	<table><tr><td>Study</td><td>Criteria used for prophylaxis</td><td>Antifungal used for prophylaxis</td><td>Invasive candidiasis</td><td>Commentary</td></tr><tr><td colspan="5">Positive prophylactic studies</td></tr><tr><td>Slotman et al.1987 [77]</td><td>Abdominal surgery+ ≥ 3 risk factors</td><td>Ketoconazole 200 mg/d POPlacebo</td><td>0/27 (0%)5/30 (17%)†</td><td>Costs: $4,800 vs. $10,000†LOS: 6.0 vs. 12.5 days†</td></tr><tr><td>Savino et al.1992 [78]</td><td>Surgical patients+ hypermetabolism</td><td>Nystatin/norfloxacin POPlacebo</td><td>6/25 (24%)13/21 (62%)‡</td><td>NI per patient:0.9 vs. 2.0†</td></tr><tr><td>Desai et al.1992 [79]</td><td>Severely burned patients</td><td>Nystatin/polymyxin SDDNo prophylaxis</td><td>34/1042 (3.3%)0/1439 (0%)†</td><td>Superficial infections:59 (21%) vs. 22 (10%)†</td></tr><tr><td>Eggimann et al.1999 [39] </td><td>Abdominal surgery+ tertiary peritonitis</td><td>Fluconazole 400 mg/d IVPlacebo</td><td>1/23 (9%)7/20 (35%)‡</td><td>Candida peritonitis1 (4%) vs. 7 (35%)†</td></tr><tr><td>Pelz et al.2001 [43] </td><td>Surgical patients+ LOS > 3 days</td><td>Fluconazole 400 mg/d POPlacebo</td><td>11/130 (8%)20/130 (15%)†</td><td>> 75% colonized at randomization</td></tr><tr><td>Garbino et al.2002 [42] </td><td>Mechanically ventilated > 96 h</td><td>Fluconazole 100 mg PO + SDDPlacebo + SDD</td><td>4/103 (4%)10/101 (10%)‡</td><td>Candidemia: 9 vs. 1(RR 0.1; CI 0.02-0.74)†</td></tr><tr><td>Jacobs et al.2003 [80] </td><td>ICU+ septic shock</td><td>Fluconazole 200 mg IV/dPlacebo</td><td>0/32 (0%)1/39 (3%)‡</td><td>Mortality significantly reduced in peritonitis</td></tr><tr><td>He et al.2003 [81]</td><td>Severe acute pancreatitis</td><td>Fluconazole 100 mg IV/dPlacebo</td><td>2/22 (9%)†7/23 (30%)†</td><td>Mortality 2/2 (100%)Mortality 3/7 (43%)</td></tr><tr><td colspan="5">Negative prophylactic studies</td></tr><tr><td>Savino et al.1994 [78]</td><td>Surgical patients+ LOS > 2 days</td><td>Nystatin 2 × 106 4 ×/d POKetoconazole 200 mg/d POClotrimazole 10 mg 3 ×/d PONo prophylaxis</td><td>5/75 (7%)1/65 (2%)‡1/80 (1%)‡2/72 (3%)‡</td><td></td></tr><tr><td>Ables et al.2000 [82]</td><td>Surgical patients+ LOS > 2 days + other risk factors</td><td>Fluconazole 3 mg/kg 3 ×/wPlacebo</td><td>8/60 (13%)11/59 (19%)‡</td><td></td></tr><tr><td>Sandven et al.2002 [40]</td><td>Surgery for peritonitis</td><td>Fluconazole 400 mg/d IVPlacebo</td><td>--</td><td>Mortality rates NS4/53 (8%) vs. 8/56 (14%)</td></tr></table>	<table><tr><td>Schuster et al.2008 [83]*</td><td>ICU ≥ 4 d+ Fever > 4 d under broad-spectrum antibiotics+ APACHE II ≥ 16</td><td>Fluconazole 400 mg/d IVPlacebo</td><td>6/122 (5%)11/127 (9%)‡</td></tr></table>
28e2083b97471052974b613071ac37e9d745a7cdc5c6ad86f1e30c4fb4c8382b.png	simple	<table><tr><td>Ptosis</td><td>Group A</td><td>Group B</td></tr><tr><td>Excellent</td><td>89% (57)</td><td>83.9% (52)</td></tr><tr><td>Good</td><td>9.4% (6)</td><td>9.7% (6)</td></tr><tr><td>Fair</td><td>1.6% (1)</td><td>6.4% (4)</td></tr><tr><td>Poor</td><td></td><td></td></tr><tr><td>Very poor</td><td></td><td></td></tr><tr><td><i>p</i> value</td><td>0.440</td><td></td></tr></table>	<table><tr><td>Ptosis</td><td>Group A</td><td>Group B</td></tr><tr><td>Excellent</td><td>89% (57)</td><td>83.9% (52)</td></tr><tr><td>Good</td><td>9.4% (6)</td><td>9.7% (6)</td></tr><tr><td>Fair</td><td>1.6% (1)</td><td>6.4% (4)</td></tr><tr><td>P</td><td></td><td></td></tr></table>	<table><tr><td>Ptosis</td><td>Group A</td><td>Group B</td></tr><tr><td>oor</td><td></td><td></td></tr><tr><td>Very poor</td><td></td><td></td></tr><tr><td>p value</td><td>0.440</td><td></td></tr></table>
e2612df633e02c397767c390e5611497d0ad65bc717ec873cfda0df22a949ffd.png	complex	<table><tr><td>NHANES 2001–2010<sup><i>a</i></sup></td><td>Sample size</td><td>Unweighted percent, %</td></tr><tr><td>All</td><td>9,568</td><td>100.0</td></tr><tr><td>Sex</td></tr><tr><td>Male</td><td>4,690</td><td>49.0</td></tr><tr><td>Female</td><td>4,878</td><td>51.0</td></tr><tr><td>Age (years)</td></tr><tr><td>16–19</td><td>938</td><td>9.80</td></tr><tr><td>20–59</td><td>7,245</td><td>75.7</td></tr><tr><td>≥ 60</td><td>1,385</td><td>14.5</td></tr><tr><td>Race/ethnicity</td></tr><tr><td>Non-Hispanic white</td><td>4,280</td><td>44.7</td></tr><tr><td>Non-Hispanic black</td><td>1,802</td><td>18.8</td></tr><tr><td>Mexican American</td><td>2,264</td><td>23.7</td></tr><tr><td>Other</td><td>1,222</td><td>12.8</td></tr><tr><td>Ratio of family income to poverty (PIR)</td></tr><tr><td>PIR < 1.0</td><td>1,669</td><td>17.5</td></tr><tr><td>1.0 ≤ PIR < 2.0</td><td>1,886</td><td>19.7</td></tr><tr><td>2.0 ≤ PIR < 3.0</td><td>1,410</td><td>14.7</td></tr><tr><td>PIR ≥ 3.0</td><td>4,603</td><td>48.1</td></tr><tr><td>Education</td></tr><tr><td>Below high school</td><td>1,689</td><td>17.6</td></tr><tr><td>High school/ general educational development </td><td>1,718</td><td>18.0</td></tr><tr><td>Some college or associate’s degree</td><td>2,592</td><td>27.1</td></tr><tr><td>College graduate or higher</td><td>2,626</td><td>27.4</td></tr><tr><td>Not reported</td><td>943</td><td>9.90</td></tr><tr><td colspan="3"><sup><i>a</i></sup>The combined data set was from five consecutive survey cycles: 2001–2002, 2003–2004, 2005–2006, 2007–2008 and 2009–2010.</td></tr></table>	<table><tr><td>NHANES 2001–2010a</td><td>Sample size</td><td>Unweighted percent, %</td></tr><tr><td>All</td><td>9,568</td><td>100.0</td></tr><tr><td>Sex</td><td colspan="2"></td></tr><tr><td>Male</td><td>4,690</td><td>49.0</td></tr><tr><td>Female</td><td>4,878</td><td>51.0</td></tr><tr><td>Age (years)</td><td colspan="2"></td></tr><tr><td>16–19</td><td>938</td><td>9.80</td></tr><tr><td>20–59</td><td>7,245</td><td>75.7</td></tr><tr><td>≥ 60</td><td>1,385</td><td>14.5</td></tr><tr><td>Race/ethnicity</td><td colspan="2"></td></tr></table>	<table><tr><td>NHANES 2001–2010a</td><td>Sample size</td><td>Unweighted percent, %</td></tr><tr><td>Non-Hispanic white</td><td>4,280</td><td>44.7</td></tr><tr><td>Non-Hispanic black</td><td>1,802</td><td>18.8</td></tr><tr><td>Mexican American</td><td>2,264</td><td>23.7</td></tr><tr><td>Other</td><td>1,222</td><td>12.8</td></tr><tr><td>Ratio of family income to poverty (PIR)</td><td colspan="2"></td></tr><tr><td>PIR < 1.0</td><td>1,669</td><td>17.5</td></tr><tr><td>1.0 ≤ PIR < 2.0</td><td>1,886</td><td>19.7</td></tr><tr><td>2.0 ≤ PIR < 3.0</td><td>1,410</td><td>14.7</td></tr><tr><td>PIR ≥ 3.0</td><td>4,603</td><td>48.1</td></tr><tr><td>Education</td><td colspan="2"></td></tr><tr><td>Below high school</td><td>1,689</td><td>17.6</td></tr><tr><td>High school/ general educational development</td><td>1,718</td><td>18.0</td></tr><tr><td>Some college or associate’s degree</td><td>2,592</td><td>27.1</td></tr><tr><td>College graduate or higher</td><td>2,626</td><td>27.4</td></tr><tr><td>Not reported</td><td>943</td><td>9.90</td></tr><tr><td colspan="3">aThe combined data set was from five consecutive survey cycles: 2001–2002, 2003–2004, 2005–2006, 2007–2008 and 2009–2010.</td></tr></table>
eaccd4fc0288068d0343323d33e1bcb631f923b1bd70c2ed401ef77da7d90e32.png	simple	<table><tr><td>Gene</td><td>Forward (5′-3′)</td><td>Reverse (5′-3′)</td></tr><tr><td>Egr1</td><td>AACAACCCTACGAGCACCTG</td><td>AAAGGGGTTCAGGCCACAAA</td></tr><tr><td>Fgf2</td><td>GCGACCCACACGTCAAACTA</td><td>CCGTGACCGGTAAGTGTTGTA</td></tr><tr><td>Fgf7</td><td>TGTGGCAATCAAAGGGGTGG</td><td>AAGGCCACGAACATTTCCCC</td></tr><tr><td>Jak2</td><td>AGTGTGCTACAGTGCTGGTC</td><td>TTCCTTGTTGCCAGATCCCG</td></tr><tr><td>Mmp9</td><td>GCCGGGAACGTATCTGGAAA</td><td>GGTTGTGGAAACTCACACGC</td></tr><tr><td>Notch2</td><td>AACTGCACCTCCTCACTTCG</td><td>CTCCTCGTTGTTGCATCCCT</td></tr><tr><td>Vim</td><td>CATGCGGCTGCGAGAAAAAT</td><td>GGTCAAGACGTGCCAGAGAA</td></tr><tr><td>Zeb2</td><td>AAAGCAGTTCCCTTCTGCGA</td><td>AGGAGCCCGAGTGTGAAAAG</td></tr><tr><td>Hif1<i>α</i></td><td>CTCATCCAAGGAGCCTTAACCT</td><td>TAACGTTCCAATTCCTGCTGC</td></tr><tr><td>Lox</td><td>AGGGCGGATGTCAGAGACTA</td><td>CATCCAGCAGGTCGTAGTGG</td></tr><tr><td>Cdh1</td><td>CCACCAGATGACGATACCCG</td><td>GAATCACTTCCGGTCTGGCA</td></tr></table>	<table><tr><td>Gene</td><td>Forward (5′-3′)</td><td>Reverse (5′-3′)</td></tr><tr><td>Eg</td><td>AACAACCCTACGAGCAC</td><td>AAAGGGGTTCAGGCCAC</td></tr></table>	<table><tr><td>r1</td><td>CTG</td><td>AAA</td></tr><tr><td>Fgf2</td><td>GCGACCCACACGTCAAACTA</td><td>CCGTGACCGGTAAGTGTTGTA</td></tr><tr><td>Fgf7</td><td>TGTGGCAATCAAAGGGGTGG</td><td>AAGGCCACGAACATTTCCCC</td></tr><tr><td>Jak2</td><td>AGTGTGCTACAGTGCTGGTC</td><td>TTCCTTGTTGCCAGATCCCG</td></tr><tr><td>Mmp9</td><td>GCCGGGAACGTATCTGGAAA</td><td>GGTTGTGGAAACTCACACGC</td></tr><tr><td>Notch2</td><td>AACTGCACCTCCTCACTTCG</td><td>CTCCTCGTTGTTGCATCCCT</td></tr><tr><td>Vim</td><td>CATGCGGCTGCGAGAAAAAT</td><td>GGTCAAGACGTGCCAGAGAA</td></tr><tr><td>Zeb2</td><td>AAAGCAGTTCCCTTCTGCGA</td><td>AGGAGCCCGAGTGTGAAAAG</td></tr><tr><td>Hif1α</td><td>CTCATCCAAGGAGCCTTAACCT</td><td>TAACGTTCCAATTCCTGCTGC</td></tr><tr><td>Lox</td><td>AGGGCGGATGTCAGAGACTA</td><td>CATCCAGCAGGTCGTAGTGG</td></tr><tr><td>Cdh1</td><td>CCACCAGATGACGATACCCG</td><td>GAATCACTTCCGGTCTGGCA</td></tr></table>
352c4bce167263351912432fa7c3e737097a94db30cf2769098f67891b53e10d.png	complex	<table><tr><td>Category</td><td>Data Elements</td></tr><tr><td rowspan="5">Vascular Access</td><td>Dialysis catheter position</td></tr><tr><td>Dialysis catheter type (acute or tunneled)</td></tr><tr><td>Dialysis catheter manufacturer</td></tr><tr><td>Dialysis catheter size</td></tr><tr><td>Any need for catheter manipulation (e.g. repositioning, replacement)</td></tr><tr><td rowspan="2">CRRT Circuit</td><td>Any circuit interruptions/replacements and reasons</td></tr><tr><td>Priming solution (new circuits)</td></tr><tr><td rowspan="3">CRRT-Related Anticoagulation</td><td>Anticoagulation type (heparin, citrate, none, other)</td></tr><tr><td>Anticoagulation dose</td></tr><tr><td>Anticoagulation metrics</td></tr><tr><td rowspan="3">CRRT Fluids</td><td>Type of solution</td></tr><tr><td>Modality (dialysate, pre- and/or post-replacement) and rate</td></tr><tr><td>Solution additives</td></tr><tr><td>CRRT Dose</td><td>Prescribed effluent dose</td></tr><tr><td rowspan="3">Machine Data Card</td><td>Delivered effluent dose</td></tr><tr><td>Type, number and duration of machine alarms and interruptions</td></tr><tr><td>Filter life</td></tr></table>	<table><tr><td>Category</td></tr><tr><td rowspan="5">Vascular Access</td></tr><tr></tr><tr></tr><tr></tr><tr></tr><tr><td rowspan="2">CRRT Circuit</td></tr><tr></tr><tr><td rowspan="3">CRRT-Related Anticoagulation</td></tr><tr></tr><tr></tr><tr><td rowspan="3">CRRT Fluids</td></tr><tr></tr><tr></tr><tr><td>CRRT Dose</td></tr><tr><td rowspan="3">Machine Data Card</td></tr><tr></tr><tr></tr></table>	<table><tr><td>Data Elements</td></tr><tr><td>Dialysis catheter position</td></tr><tr><td>Dialysis catheter type (acute or tunneled)</td></tr><tr><td>Dialysis catheter manufacturer</td></tr><tr><td>Dialysis catheter size</td></tr><tr><td>Any need for catheter manipulation (e.g. repositioning, replacement)</td></tr><tr><td>Any circuit interruptions/replacements and reasons</td></tr><tr><td>Priming solution (new circuits)</td></tr><tr><td>Anticoagulation type (heparin, citrate, none, other)</td></tr><tr><td>Anticoagulation dose</td></tr><tr><td>Anticoagulation metrics</td></tr><tr><td>Type of solution</td></tr><tr><td>Modality (dialysate, pre- and/or post-replacement) and rate</td></tr><tr><td>Solution additives</td></tr><tr><td>Prescribed effluent dose</td></tr><tr><td>Delivered effluent dose</td></tr><tr><td>Type, number and duration of machine alarms and interruptions</td></tr><tr><td>Filter life</td></tr></table>
fabf18c090f7d349bebed00f083ee4644892745624b2651ae2edabd0415708bd.png	complex	<table><tr><td>Name</td><td>Description</td><td>Reference</td></tr><tr><td colspan="3">Integrative plasmid set with <i>URA3</i> selection marker flanked with direct repeats</td></tr><tr><td> pCfB126</td><td>pX-2-USER-URA3-DR</td><td>Mikkelsen <i>et al</i>. (2012)</td></tr><tr><td> pCfB127</td><td>pX-3-USER-URA3-DR</td><td>Mikkelsen <i>et al</i>. (2012)</td></tr><tr><td> pCfB128</td><td>pX-4-USER-URA3-DR</td><td>Mikkelsen <i>et al</i>. (2012)</td></tr><tr><td> pCfB383</td><td>pXI-1-USER-URA3-DR</td><td>Mikkelsen <i>et al</i>. (2012)</td></tr><tr><td> pCfB384</td><td>pXI-2-USER-URA3-DR</td><td>Mikkelsen <i>et al</i>. (2012)</td></tr><tr><td> pCfB385</td><td>pXI-3-USER-URA3-DR</td><td>Mikkelsen <i>et al</i>. (2012)</td></tr><tr><td> pCfB387</td><td>pXI-5-USER-URA3-DR</td><td>Mikkelsen <i>et al</i>. (2012)</td></tr><tr><td> pCfB129</td><td>pXII-1-USER-URA3-DR</td><td>Mikkelsen <i>et al</i>. (2012)</td></tr><tr><td> pCfB120</td><td>pXII-2-USER-URA3-DR</td><td>Mikkelsen <i>et al</i>. (2012)</td></tr><tr><td> pCfB130</td><td>pXII-4-USER-URA3-DR</td><td>Mikkelsen <i>et al</i>. (2012)</td></tr><tr><td> pCfB131</td><td>pXII-5-USER-URA3-DR</td><td>Mikkelsen <i>et al</i>. (2012)</td></tr><tr><td> pCfB49</td><td>pXII-1-ccdB-USER-URA3-DR</td><td>Mikkelsen <i>et al</i>. (2012)</td></tr><tr><td colspan="3">Plasmids that contain LoxP-flanked selection marker cassettes</td></tr><tr><td> pUG6</td><td>LoxP-KanMX</td><td>Gueldener <i>et al</i>. (2002)</td></tr><tr><td> pUG27</td><td>LoxP-SpHIS5</td><td>Gueldener <i>et al</i>. (2002)</td></tr><tr><td> pUG72</td><td>LoxP-KlURA3</td><td>Gueldener <i>et al</i>. (2002)</td></tr><tr><td> pUG73</td><td>LoxP-KlLEU2</td><td>Gueldener <i>et al</i>. (2002)</td></tr><tr><td> pSA40</td><td>LoxP-CaLYS5</td><td>Ito-Harashima & McCusker (2004)</td></tr><tr><td colspan="3">Episomal replication vectors with USER cassette (the vectors were derived from pESC vector series, Agilent)</td></tr><tr><td> pCfB54</td><td>pESC-URA-ccdB-USER</td><td>This study</td></tr><tr><td> pCfB55</td><td>pESC-HIS-ccdB-USER</td><td>This study</td></tr><tr><td> pCfB132</td><td>pESC-URA-USER</td><td>This study</td></tr><tr><td> pCfB291</td><td>pESC-HIS-USER</td><td>This study</td></tr><tr><td> pCfB220</td><td>pESC-LEU-USER</td><td>This study</td></tr><tr><td colspan="3">EasyClone integrative vector set with loxP-flanked selection markers</td></tr><tr><td> pCfB255</td><td>pX-2-LoxP-KlURA3</td><td>This study</td></tr><tr><td> pCfB353</td><td>pX-2-LoxP-KanMX</td><td>This study</td></tr><tr><td> pCfB257</td><td>pX-3-LoxP-KlLEU2</td><td>This study</td></tr><tr><td> pCfB258</td><td>pX-4-LoxP-SpHIS5</td><td>This study</td></tr><tr><td> pCfB388</td><td>pXI-1-LoxP-KlLEU2</td><td>This study</td></tr><tr><td> pCfB389</td><td>pXI-2-LoxP-KlURA3</td><td>This study</td></tr><tr><td> pCfB390</td><td>pXI-3-LoxP-KlURA3</td><td>This study</td></tr><tr><td> pCfB391</td><td>pXI-5-LoxP-SpHIS5</td><td>This study</td></tr><tr><td> pCfB259</td><td>pXII-1-LoxP-KlLEU2</td><td>This study</td></tr><tr><td> pCfB260</td><td>pXII-2-LoxP-CaLYS5</td><td>This study</td></tr><tr><td> pCfB262</td><td>pXII-4-LoxP-SpHIS5</td><td>This study</td></tr><tr><td> pCfB261</td><td>pXII-5-LoxP-SpHIS5</td><td>This study</td></tr><tr><td colspan="3">Plasmids containing genes encoding fluorescent proteins</td></tr><tr><td> pWJ1163</td><td>CFP</td><td>Reid <i>et al</i>. (2002)</td></tr><tr><td> pWJ1165</td><td>YFP</td><td>Reid <i>et al</i>. (2002)</td></tr><tr><td> pWJ1350</td><td>RFP</td><td>Lisby <i>et al</i>. (2003)</td></tr><tr><td colspan="3">EasyClone vectors for expression of genes for fluorescent proteins in <i>S. cerevisiae</i></td></tr><tr><td> pCfB393</td><td>pX-2-LoxP-KlURA3-TEF1::CFP</td><td>This study</td></tr><tr><td> pCfB394</td><td>pX-3-LoxP-KlLEU2-TEF1::RFP</td><td>This study</td></tr><tr><td> pCfB395</td><td>pX-4- LoxP-SpHiS5-TEF1::YFP</td><td>This study</td></tr><tr><td colspan="3">Episomal vectors for expression of genes for fluorescent proteins in <i>S. cerevisiae</i></td></tr><tr><td> pCfB396</td><td>pESC-URA-USER-TEF1::CFP</td><td>This study</td></tr><tr><td> pCfB397</td><td>pESC-LEU-USER-TEF1::RFP</td><td>This study</td></tr><tr><td> pCfB398</td><td>pESC-HIS-USER-TEF1::YFP</td><td>This study</td></tr><tr><td colspan="3">Plasmid contains a cassette for expression of GFP in <i>E. coli</i> (used as positive control in USER cloning)</td></tr><tr><td> pCfB774</td><td>pmExpCtrl</td><td>Dr Hao Lao, DTU</td></tr></table>	<table><tr><td>Name</td><td>Description</td><td>Reference</td></tr><tr><td colspan="3">Integrative plasmid set with URA3 selection marker flanked with direct repeats</td></tr><tr><td>pCfB126</td><td>pX-2-USER-URA3-DR</td><td>Mikkelsen et al. (2012)</td></tr><tr><td>pCfB127</td><td>pX-3-USER-URA3-DR</td><td>Mikkelsen et al. (2012)</td></tr><tr><td>pCfB128</td><td>pX-4-USER-URA3-DR</td><td>Mikkelsen et al. (2012)</td></tr><tr><td>pCfB383</td><td>pXI-1-USER-URA3-DR</td><td>Mikkelsen et al. (2012)</td></tr><tr><td>pCfB384</td><td>pXI-2-USER-URA3-DR</td><td>Mikkelsen et al. (2012)</td></tr><tr><td>pCfB385</td><td>pXI-3-USER-URA3-DR</td><td>Mikkelsen et al. (2012)</td></tr><tr><td>pCf</td><td>pXI-5-USER-URA3-</td><td>Mikkelsen et </td></tr></table>	<table><tr><td>Name</td><td>Description</td><td>Reference</td></tr><tr><td>B387</td><td>DR</td><td>al. (2012)</td></tr><tr><td>pCfB129</td><td>pXII-1-USER-URA3-DR</td><td>Mikkelsen et al. (2012)</td></tr><tr><td>pCfB120</td><td>pXII-2-USER-URA3-DR</td><td>Mikkelsen et al. (2012)</td></tr><tr><td>pCfB130</td><td>pXII-4-USER-URA3-DR</td><td>Mikkelsen et al. (2012)</td></tr><tr><td>pCfB131</td><td>pXII-5-USER-URA3-DR</td><td>Mikkelsen et al. (2012)</td></tr><tr><td>pCfB49</td><td>pXII-1-ccdB-USER-URA3-DR</td><td>Mikkelsen et al. (2012)</td></tr><tr><td colspan="3">Plasmids that contain LoxP-flanked selection marker cassettes</td></tr><tr><td>pUG6</td><td>LoxP-KanMX</td><td>Gueldener et al. (2002)</td></tr><tr><td>pUG27</td><td>LoxP-SpHIS5</td><td>Gueldener et al. (2002)</td></tr><tr><td>pUG72</td><td>LoxP-KlURA3</td><td>Gueldener et al. (2002)</td></tr><tr><td>pUG73</td><td>LoxP-KlLEU2</td><td>Gueldener et al. (2002)</td></tr><tr><td>pSA40</td><td>LoxP-CaLYS5</td><td>Ito-Harashima & McCusker (2004)</td></tr><tr><td colspan="3">Episomal replication vectors with USER cassette (the vectors were derived from pESC vector series, Agilent)</td></tr><tr><td>pCfB54</td><td>pESC-URA-ccdB-USER</td><td>This study</td></tr><tr><td>pCfB55</td><td>pESC-HIS-ccdB-USER</td><td>This study</td></tr><tr><td>pCfB132</td><td>pESC-URA-USER</td><td>This study</td></tr><tr><td>pCfB291</td><td>pESC-HIS-USER</td><td>This study</td></tr><tr><td>pCfB220</td><td>pESC-LEU-USER</td><td>This study</td></tr><tr><td colspan="3">EasyClone integrative vector set with loxP-flanked selection markers</td></tr><tr><td>pCfB255</td><td>pX-2-LoxP-KlURA3</td><td>This study</td></tr><tr><td>pCfB353</td><td>pX-2-LoxP-KanMX</td><td>This study</td></tr><tr><td>pCfB257</td><td>pX-3-LoxP-KlLEU2</td><td>This study</td></tr><tr><td>pCfB258</td><td>pX-4-LoxP-SpHIS5</td><td>This study</td></tr><tr><td>pCfB388</td><td>pXI-1-LoxP-KlLEU2</td><td>This study</td></tr><tr><td>pCfB389</td><td>pXI-2-LoxP-KlURA3</td><td>This study</td></tr><tr><td>pCfB390</td><td>pXI-3-LoxP-KlURA3</td><td>This study</td></tr><tr><td>pCfB391</td><td>pXI-5-LoxP-SpHIS5</td><td>This study</td></tr><tr><td>pCfB259</td><td>pXII-1-LoxP-KlLEU2</td><td>This study</td></tr><tr><td>pCfB260</td><td>pXII-2-LoxP-CaLYS5</td><td>This study</td></tr><tr><td>pCfB262</td><td>pXII-4-LoxP-SpHIS5</td><td>This study</td></tr><tr><td>pCfB261</td><td>pXII-5-LoxP-SpHIS5</td><td>This study</td></tr><tr><td colspan="3">Plasmids containing genes encoding fluorescent proteins</td></tr><tr><td>pWJ1163</td><td>CFP</td><td>Reid et al. (2002)</td></tr><tr><td>pWJ1165</td><td>YFP</td><td>Reid et al. (2002)</td></tr><tr><td>pWJ1350</td><td>RFP</td><td>Lisby et al. (2003)</td></tr><tr><td colspan="3">EasyClone vectors for expression of genes for fluorescent proteins in S. cerevisiae</td></tr><tr><td>pCfB393</td><td>pX-2-LoxP-KlURA3-TEF1::CFP</td><td>This study</td></tr><tr><td>pCfB394</td><td>pX-3-LoxP-KlLEU2-TEF1::RFP</td><td>This study</td></tr><tr><td>pCfB395</td><td>pX-4- LoxP-SpHiS5-TEF1::YFP</td><td>This study</td></tr><tr><td colspan="3">Episomal vectors for expression of genes for fluorescent proteins in S. cerevisiae</td></tr><tr><td>pCfB396</td><td>pESC-URA-USER-TEF1::CFP</td><td>This study</td></tr><tr><td>pCfB397</td><td>pESC-LEU-USER-TEF1::RFP</td><td>This study</td></tr><tr><td>pCfB398</td><td>pESC-HIS-USER-TEF1::YFP</td><td>This study</td></tr><tr><td colspan="3">Plasmid contains a cassette for expression of GFP in E. coli (used as positive control in USER cloning)</td></tr><tr><td>pCfB774</td><td>pmExpCtrl</td><td>Dr Hao Lao, DTU</td></tr></table>
ff69e56110217af774f0516f687031ad5779c017a0c16065aeef5575dff1a650.png	simple	<table><tr><td></td><td>Specificity (%)</td><td>Sensitivity (%)</td><td>AUC</td><td>Confidence interval</td></tr><tr><td>Roc 1 (Both H&R scores >0)</td><td>83.3</td><td>61.1</td><td>72.3</td><td>63.61–82.22 %</td></tr><tr><td>Roc 2 (Both H&R scores >1)</td><td>81.4</td><td>67.8</td><td>75.3</td><td>65.66–85.79 %</td></tr><tr><td>Roc 3 (Both H&R scores >2)</td><td>77.5</td><td>81.2</td><td>80.9</td><td>69.49–92.24 %</td></tr><tr><td>Roc 4 (Both H&R scores >3)</td><td>71.8</td><td>100.0</td><td>89.1</td><td>79.9 %–98.2 %</td></tr></table>	<table><tr><td></td><td>Specificity (%)</td></tr><tr><td>Roc 1 (Both H&R scores >0)</td><td>83.3</td></tr><tr><td>Roc 2 (Both H&R scores >1)</td><td>81.4</td></tr><tr><td>Roc 3 (Both H&R scores >2)</td><td>77.5</td></tr><tr><td>Roc 4 (Both H&R scores >3)</td><td>71.8</td></tr></table>	<table><tr><td>Sensitivity (%)</td><td>AUC</td><td>Confidence interval</td></tr><tr><td>61.1</td><td>72.3</td><td>63.61–82.22 %</td></tr><tr><td>67.8</td><td>75.3</td><td>65.66–85.79 %</td></tr><tr><td>81.2</td><td>80.9</td><td>69.49–92.24 %</td></tr><tr><td>100.0</td><td>89.1</td><td>79.9 %–98.2 %</td></tr></table>
5d9d0331778fe8389db8f27df0967019ccdda0ac8ccbb0dd43994a69f73d7e47.png	simple	<table><tr><td></td><td>PA-PRP (<i>n</i> = 11)</td><td>HA (<i>n</i> = 10)</td></tr><tr><td>Age, mean (SD) years</td><td>49.91 (13.72)</td><td>52.70 (10.30)</td></tr><tr><td>BMI, mean (SD) kg/m<sup>2</sup></td><td>27.92 (11.94)</td><td>30.87 (5.64)</td></tr><tr><td>Previous surgery, no. (%)</td><td>5 (45 %)</td><td>8 (80 %)</td></tr><tr><td>Gender (Male), no. (%)</td><td>8 (72.73 %)</td><td>7 (70 %)</td></tr><tr><td>Symptom duration, mean (SD) years</td><td>8.50 (4.95)</td><td>15 (7.07)</td></tr><tr><td>Cause of osteoarthritis, no.</td><td></td><td></td></tr><tr><td> Degeneration/unknown</td><td>6</td><td>4</td></tr><tr><td> Post joint injury/surgery</td><td>3</td><td>3</td></tr><tr><td> Sport related degeneration</td><td>2</td><td>3</td></tr></table>	<table><tr><td></td></tr><tr><td>Age, mean (SD) years</td></tr><tr><td>BMI, mean (SD) kg/m2</td></tr><tr><td>Previous surgery, no. (%)</td></tr><tr><td>Gender (Male), no. (%)</td></tr><tr><td>Symptom duration, mean (SD) years</td></tr><tr><td>Cause of osteoarthritis, no.</td></tr><tr><td>Degeneration/unknown</td></tr><tr><td>Post joint injury/surgery</td></tr><tr><td>Sport related degeneration</td></tr></table>	<table><tr><td>PA-PRP (n = 11)</td><td>HA (n = 10)</td></tr><tr><td>49.91 (13.72)</td><td>52.70 (10.30)</td></tr><tr><td>27.92 (11.94)</td><td>30.87 (5.64)</td></tr><tr><td>5 (45 %)</td><td>8 (80 %)</td></tr><tr><td>8 (72.73 %)</td><td>7 (70 %)</td></tr><tr><td>8.50 (4.95)</td><td>15 (7.07)</td></tr><tr><td></td><td></td></tr><tr><td>6</td><td>4</td></tr><tr><td>3</td><td>3</td></tr><tr><td>2</td><td>3</td></tr></table>
59e466818280b4311fdf06afb0e03baddd579f9b12960abd754533c280aec613.png	complex	<table><tr><td colspan="2"></td><td>AML(n=11)</td><td>ALL(n=9)</td><td>MM(n=26)</td><td>NHL(n=6)</td><td>HL(n=12)</td><td>P value</td></tr><tr><td colspan="2">IL-6 (pg/mL)</td><td>95.10(55.10-140.90)</td><td>89.90 (61.90-690)</td><td>91.25(4.5-640)</td><td>68.10(33-152.9)</td><td>72.70(32-530)</td><td>0.25</td></tr><tr><td>IL-10 (pg/mL)</td><td colspan="2">86.20(68.50-640)</td><td>75.90(26-133.9)</td><td>87.75(41.40-588)</td><td>93.86(55-112)</td><td>86.05(58.20-215)</td><td>0.25</td></tr><tr><td colspan="2">hs-CRP (mg/L)</td><td>3(1-14)</td><td>3(1-6)</td><td>3(1-71)</td><td>7(3-75)</td><td>3(3-75)</td><td>0.07</td></tr><tr><td colspan="2">IL-6 / IL-10</td><td>1.01(0.12-1.87)</td><td>1.28(0.73-4.78)</td><td>1.04(0.01 -8.59)</td><td>0.84(0.29-1.60)</td><td>0.76(0.22 -5.22)</td><td>0.21</td></tr></table>	<table><tr><td colspan="2"></td><td>AML(n=11)</td><td>ALL(n=9)</td><td>MM(n=26)</td></tr><tr><td colspan="2">IL-6 (pg/mL)</td><td>95.10(55.10-140.90)</td><td>89.90 (61.90-690)</td><td>91.25(4.5-640)</td></tr><tr><td>IL-10 (pg/mL)</td><td colspan="2">86.20(68.50-640)</td><td>75.90(26-133.9)</td><td>87.75(41.40-588)</td></tr><tr><td colspan="2">hs-CRP (mg/L)</td><td>3(1-14)</td><td>3(1-6)</td><td>3(1-71)</td></tr><tr><td colspan="2">IL-6 / IL-10</td><td>1.01(0.12-1.87)</td><td>1.28(0.73-4.78)</td><td>1.04(0.01 -8.59)</td></tr></table>	<table><tr><td>NHL(n=6)</td><td>HL(n=12)</td><td>P value</td></tr><tr><td>68.10(33-152.9)</td><td>72.70(32-530)</td><td>0.25</td></tr><tr><td>93.86(55-112)</td><td>86.05(58.20-215)</td><td>0.25</td></tr><tr><td>7(3-75)</td><td>3(3-75)</td><td>0.07</td></tr><tr><td>0.84(0.29-1.60)</td><td>0.76(0.22 -5.22)</td><td>0.21</td></tr></table>
225a8efed3cedc97320fc1821a74af5639218c81ff4d316cc189ca6502a6658d.png	complex	<table><tr><td colspan="4">Holistic wellness/well-being (encompassing each of physical, psychological, social, spiritual)</td></tr><tr><td>Physical</td><td>Psychological</td><td>Social</td><td>Spiritual</td></tr><tr><td>Biological markers</td><td>Absorption</td><td>Adjustment</td><td>Awareness</td></tr><tr><td>Disability</td><td>Anger</td><td>Advocacy</td><td>Balance</td></tr><tr><td>Energy</td><td>Anxiety</td><td>Economic</td><td>Enablement</td></tr><tr><td>Fatigue</td><td>Attitudes and Beliefs</td><td> Health care utilization</td><td>Energy</td></tr><tr><td>Function/Activities of Daily Living</td><td>Awareness</td><td> Cost-effectiveness</td><td>Harmony</td></tr><tr><td>Pain</td><td>Coping</td><td>Relationships</td><td>Hope</td></tr><tr><td>Pathology</td><td>Depression</td><td>Role function in daily life and work</td><td>Peace</td></tr><tr><td>Sleep</td><td>Empathy</td><td>Social support</td><td>Relaxation</td></tr><tr><td>Symptom management</td><td>Enablement</td><td>Socioeconomic</td><td>Spirituality</td></tr><tr><td></td><td>Energy</td><td>Social Strain</td><td>Transformation</td></tr><tr><td></td><td>Patient expectations</td><td>Religiosity</td><td></td></tr><tr><td></td><td>General</td><td></td><td></td></tr><tr><td></td><td>Hope</td><td></td><td></td></tr><tr><td></td><td>Introversion</td><td></td><td></td></tr><tr><td></td><td>Locus of control</td><td></td><td></td></tr><tr><td></td><td>Mood</td><td></td><td></td></tr><tr><td></td><td>Openness to experience</td><td></td><td></td></tr><tr><td></td><td>Optimism/Pessimism</td><td></td><td></td></tr><tr><td></td><td>Patient knowledge</td><td></td><td></td></tr><tr><td></td><td>Patient motivation</td><td></td><td></td></tr><tr><td></td><td>Patient perceived self-efficacy</td><td></td><td></td></tr><tr><td></td><td>Patient perceptions of care</td><td></td><td></td></tr><tr><td></td><td>Patient perceptions of risk</td><td></td><td></td></tr><tr><td></td><td>Patient preference for control</td><td></td><td></td></tr><tr><td></td><td>Patient Satisfaction</td><td></td><td></td></tr><tr><td></td><td>Readiness</td><td></td><td></td></tr><tr><td></td><td>Relaxation</td><td></td><td></td></tr><tr><td></td><td>Resilience</td><td></td><td></td></tr><tr><td></td><td>Self-Esteem</td><td></td><td></td></tr><tr><td></td><td>Sense of Coherence</td><td></td><td></td></tr><tr><td></td><td>Stress</td><td></td><td></td></tr><tr><td></td><td>Trust</td><td></td><td></td></tr><tr><td colspan="4">Quality of Life (assessing at least two of physical, psychological, social, spiritual)</td></tr><tr><td colspan="4">Global</td></tr><tr><td colspan="4">Multidimensional</td></tr><tr><td colspan="4">Individualized</td></tr><tr><td colspan="4">e.g. Measure Your Medical Outcome Profile, Measure Your Concerns and Well-being, Goal Attainment Scaling</td></tr><tr><td colspan="4">Context of healing</td></tr><tr><td colspan="4">Healing environment</td></tr><tr><td colspan="4">Negotiations between patients and practitioners</td></tr><tr><td colspan="4">Patient-centeredness of healing</td></tr><tr><td colspan="4">Patient expectations</td></tr><tr><td colspan="4">Patient-practitioner relationship</td></tr><tr><td colspan="4">Practitioner attitudes towards integration</td></tr><tr><td colspan="4">Practitioner attributes</td></tr><tr><td colspan="4">Practitioner expectations</td></tr><tr><td colspan="4">Practitioner experience</td></tr><tr><td colspan="4">Attunement</td></tr><tr><td colspan="4">Therapeutic Intent</td></tr><tr><td colspan="4">Process of healing</td></tr><tr><td colspan="4">Adjustment</td></tr><tr><td colspan="4">Engagement with intervention experience</td></tr><tr><td colspan="4">Personal growth</td></tr><tr><td colspan="4">Transformation</td></tr><tr><td colspan="4">Unstuckness</td></tr></table>	<table><tr><td colspan="4">Holistic wellness/well-being (encompassing each of physical, psychological, social, spiritual)</td></tr><tr><td>Physical</td><td>Psychological</td><td>Social</td><td>Spiritual</td></tr><tr><td>Biological markers</td><td>Absorption</td><td>Adjustment</td><td>Awareness</td></tr><tr><td>Disability</td><td>Anger</td><td>Advocacy</td><td>Balance</td></tr><tr><td>Energy</td><td>Anxiety</td><td>Economic</td><td>Enablement</td></tr><tr><td>Fatigue</td><td>Attitudes and Beliefs</td><td>Health care utilization</td><td>Energy</td></tr><tr><td>Function/Activities of Daily Living</td><td>Awareness</td><td>Cost-effectiveness</td><td>Harmony</td></tr><tr><td>Pain</td><td>Coping</td><td>Relationships</td><td>Hope</td></tr><tr><td>Pathology</td><td>Depression</td><td>Role function in daily life and work</td><td>Peace</td></tr><tr><td>Sleep</td><td>Empathy</td><td>Social support</td><td>Relaxation</td></tr><tr><td>Symptom management</td><td>Enablement</td><td>Socioeconomic</td><td>Spirituality</td></tr><tr><td></td><td>Energy</td><td>Social Strain</td><td>Transformation</td></tr><tr><td></td><td>Patient expectations</td><td>Religiosity</td><td></td></tr><tr><td></td><td>General</td><td></td><td></td></tr><tr><td></td><td>Hope</td><td></td><td></td></tr><tr><td></td><td>Introversion</td><td></td><td></td></tr><tr><td></td><td>Locus of control</td><td></td><td></td></tr><tr><td></td><td>Mood</td><td></td><td></td></tr><tr><td></td><td>Openness to experience</td><td></td><td></td></tr><tr><td></td><td>Optimism/Pessimism</td><td></td><td></td></tr><tr><td></td><td>Patient knowledge</td><td></td><td></td></tr><tr><td></td><td>Patient motivation</td><td></td><td></td></tr><tr><td></td><td>Patient perceived self-efficacy</td><td></td><td></td></tr><tr><td></td><td>Patient perceptions of care</td><td></td><td></td></tr><tr><td></td><td>Patient perceptions of risk</td><td></td><td></td></tr><tr><td></td><td>Patient preference for control</td><td></td><td></td></tr><tr><td></td><td>Patient Satisfaction</td><td></td><td></td></tr><tr><td></td><td>Readiness</td><td></td><td></td></tr><tr><td></td><td>Relaxation</td><td></td><td></td></tr><tr><td></td><td>Resilience</td><td></td><td></td></tr><tr><td></td><td>Self-Esteem</td><td></td><td></td></tr><tr><td></td><td>Sense of Coherence</td><td></td><td></td></tr><tr><td></td><td>Stress</td><td></td><td></td></tr><tr><td></td><td>Trust</td><td></td><td></td></tr><tr><td colspan="4">Quality of Life (assessing at least two of physical, psychological, social, spiritual)</td></tr><tr><td colspan="4">Global</td></tr><tr><td colspan="4">Multidimensional</td></tr><tr><td colspan="4">Individualized</td></tr><tr><td colspan="4">e.g. Measure Your Medical Outcome Profile, Measure Your Concerns and Well-being, Goal Attainment Scaling</td></tr><tr><td colspan="4">Context of healing</td></tr><tr><td colspan="4">Healing environment</td></tr><tr><td colspan="4">Negotiations between patients and practitioners</td></tr><tr><td colspan="4">Patient-centeredness of healing</td></tr></table>	<table><tr><td colspan="4">Holistic wellness/well-being (encompassing each of physical, psychological, social, spiritual)</td></tr><tr><td colspan="4">Patient expectations</td></tr><tr><td colspan="4">Patient-practitioner relationship</td></tr><tr><td colspan="4">Practitioner attitudes towards integration</td></tr><tr><td colspan="4">Practitioner attributes</td></tr><tr><td colspan="4">Practitioner expectations</td></tr><tr><td colspan="4">Practitioner experience</td></tr><tr><td colspan="4">Attunement</td></tr><tr><td colspan="4">Therapeutic Intent</td></tr><tr><td colspan="4">Process of healing</td></tr><tr><td colspan="4">Adjustment</td></tr><tr><td colspan="4">Engagement with intervention experience</td></tr><tr><td colspan="4">Personal growth</td></tr><tr><td colspan="4">Transformation</td></tr><tr><td colspan="4">Unstuckness</td></tr></table>
72b5eba9cf53dcaab08a1d0a4b1f14806eadd15ee88613515fa36c2d563240ae.png	simple	<table><tr><td>Rotarix<sup>® </sup>label</td><td>"In the manufacturing process, porcine-derived materials are used.Porcine circovirus type 1 (PCV-1) is present in Rotarix. PCV-1 is not known to cause disease in humans."</td></tr><tr><td>RotaTeqTM label</td><td>"In the manufacturing process for RotaTeq, a porcine-derived material is used. DNA from porcine circoviruses (PCV) 1 and 2 has been detected in RotaTeq. PCV-1 and PCV-2 are not known to cause disease in humans."</td></tr></table>	<table><tr><td>Rotarix® label</td><td>"In the manufacturing process, porcine-derived materials are used.Porcine circovirus type 1 (PCV-1) is present in Rotarix. PCV-1 is not known to cause disease in humans."</td></tr></table>	<table><tr><td>RotaTeqTM label</td><td>"In the manufacturing process for RotaTeq, a porcine-derived material is used. DNA from porcine circoviruses (PCV) 1 and 2 has been detected in RotaTeq. PCV-1 and PCV-2 are not known to cause disease in humans."</td></tr></table>
289212ed4ab09b7fceea8003c095be736131097335e13f93fed46bc78fbdea1b.png	simple	<table><tr><td>Probe set ID</td><td>Gene Symbol</td><td>Gene Title</td><td>Fold Change in Apc<sup><i>fl</i>/<i>fl </i></sup>p53<sup>-/- </sup>v WT</td></tr><tr><td>1418368_at</td><td>Retnlb</td><td>resistin like beta</td><td>0.002</td></tr><tr><td>1422422_at</td><td>Defcr4</td><td>defensin related cryptdin 4</td><td>27.73</td></tr><tr><td>1425221_at</td><td>Agr3</td><td>anterior gradient homolog 3 (Xenopus laevis)</td><td>27.20</td></tr><tr><td>1460582_x_at</td><td>a</td><td>Nonagouti</td><td>17.82</td></tr><tr><td>1421837_at</td><td>Rps18</td><td>ribosomal protein S18</td><td>8.12</td></tr><tr><td>1422934_x_at</td><td>Defcr-rs7</td><td>defensin related cryptdin, related sequence 7</td><td>30.91</td></tr><tr><td>452183_a_at</td><td>Gtl2</td><td>GTL2, imprinted maternally expressed untranslated mRNA</td><td>25.82</td></tr><tr><td>1421838_at</td><td>Rps18</td><td>ribosomal protein S18</td><td>8.60</td></tr><tr><td>1459443_at</td><td>Kcnq1</td><td>Potassium voltage-gated channel, subfamily Q, member 1</td><td>9.67</td></tr><tr><td>1447260_at</td><td>ENSMUSG000000734</td><td>ENSMUSG00000073403</td><td>12.11</td></tr><tr><td>1426340_at</td><td>Slc1a3</td><td>solute carrier family 1 (glial high affinity glutamate transporter), member 3</td><td>13.83</td></tr><tr><td>1455274_at</td><td>a</td><td>Nonagouti</td><td>19.31</td></tr><tr><td>1422071_at</td><td>Lgals6</td><td>lectin, galactose binding, soluble 6</td><td>11.52</td></tr><tr><td>1420748_a_at</td><td>Adat1</td><td>adenosine deaminase, tRNA-specific 1</td><td>4.33</td></tr><tr><td>1423017_a_at</td><td>Il1rn</td><td>interleukin 1 receptor antagonist</td><td>12.54</td></tr><tr><td>1449492_a_at</td><td>Lect2</td><td>leukocyte cell-derived chemotaxin 2</td><td>43.73</td></tr><tr><td>1443536_at</td><td>Slc7a11</td><td>solute carrier family 7 (cationic amino acid transporter, y+ system), member 11</td><td>13.16</td></tr><tr><td>1446728_at</td><td>D3Ertd797e</td><td>DNA segment, Chr 3, ERATO Doi 797, expressed</td><td>2.39</td></tr><tr><td>1459779_s_at</td><td>Setd8</td><td>SET domain containing (lysine methyltransferase) 8</td><td>6.92</td></tr><tr><td>1421257_at</td><td>Pigb</td><td>phosphatidylinositol glycan anchor biosynthesis, class B</td><td>11.65</td></tr><tr><td>1446730_at</td><td>C79267</td><td>Expressed sequence C79267</td><td>10.65</td></tr><tr><td>1459834_x_at</td><td>---</td><td>---</td><td>4.64</td></tr><tr><td>1460604_at</td><td>Cybrd1</td><td>cytochrome b reductase 1</td><td>22.55</td></tr><tr><td>1427580_a_at</td><td>Rian</td><td>RNA imprinted and accumulated in nucleus</td><td>9.54</td></tr><tr><td>1418708_at</td><td>Apoc4</td><td>apolipoprotein C-IV</td><td>19.03</td></tr><tr><td>1422597_at</td><td>Mmp15</td><td>matrix metallopeptidase 15</td><td>10.55</td></tr><tr><td>1434734_at</td><td>E130016E03Rik</td><td>RIKEN cDNA E130016E03 gene</td><td>9.11</td></tr><tr><td>1441594_at</td><td>---</td><td>---</td><td>5.86</td></tr><tr><td>1441624_at</td><td>Sorbs2</td><td>sorbin and SH3 domain containing 2</td><td>3.78</td></tr><tr><td>1434028_at</td><td>Arnt2</td><td>aryl hydrocarbon receptor nuclear translocator 2</td><td>11.43</td></tr><tr><td>1427967_at</td><td>Srgap2</td><td>SLIT-ROBO Rho GTPase activating protein 2</td><td>9.36</td></tr><tr><td>1434497_at</td><td>4933431E20Rik</td><td>RIKEN cDNA 4933431E20 gene</td><td>7.73</td></tr><tr><td>1444538_at</td><td>Snd1</td><td>Staphylococcal nuclease and tudor domain containing 1</td><td>8.68</td></tr><tr><td>1457636_x_at</td><td>---</td><td>---</td><td>5.12</td></tr><tr><td>1436845_at</td><td>Axin2</td><td>axin2</td><td>4.58</td></tr><tr><td>1457262_at</td><td>2610207I05Rik</td><td>RIKEN cDNA 2610207I05 gene</td><td>5.35</td></tr><tr><td>1431031_at</td><td>Arid4b</td><td>AT rich interactive domain 4B (Rbp1 like)</td><td>3.55</td></tr><tr><td>1439380_x_at</td><td>Gtl2</td><td>GTL2, imprinted maternally expressed untranslated mRNA</td><td>7.69</td></tr><tr><td>1417520_at</td><td>Nfe2l3</td><td>nuclear factor, erythroid derived 2, like 3</td><td>6.40</td></tr><tr><td>1446376_at</td><td>Rps6kb1</td><td>ribosomal protein S6 kinase, polypeptide 1</td><td>5.88</td></tr><tr><td>1422882_at</td><td>Sypl</td><td>synaptophysin-like protein</td><td>4.91</td></tr><tr><td>1444498_at</td><td>---</td><td>---</td><td>7.23</td></tr><tr><td>1438258_at</td><td>Vldlr</td><td>very low density lipoprotein receptor</td><td>6.85</td></tr><tr><td>1422954_at</td><td>Zfp60</td><td>zinc finger protein 60</td><td>3.25</td></tr><tr><td>1425986_a_at</td><td>Dcun1d</td><td>DCUN1D1 DCN1, defective in cullin neddylation 1, domain containing 1 (S. cerevisiae)</td><td>2.49</td></tr><tr><td>1430458_at</td><td>Supt6h</td><td>suppressor of Ty 6 homolog (S. cerevisiae)</td><td>3.17</td></tr><tr><td>1434734_at</td><td>E130016E03Rik</td><td>RIKEN cDNA E130016E03 gene</td><td>9.11</td></tr><tr><td>1435082_at</td><td>Syp1</td><td>synaptophysin-like protein</td><td>5.30</td></tr><tr><td>1437065_at</td><td>Zbtb20</td><td>zinc finger and BTB domain containing 20</td><td>12.39</td></tr><tr><td>1441487_at</td><td>Trim2</td><td>tripartite motif protein 2</td><td>5.68</td></tr><tr><td>1443628_at</td><td>---</td><td>---</td><td>9.06</td></tr><tr><td>1447386_at</td><td>Usp2</td><td>Ubiquitin specific peptidase 8</td><td>2.94</td></tr><tr><td>1455327_at</td><td>Senp2</td><td>SUMO/sentrin specific peptidase 2</td><td>4.36</td></tr></table>	<table><tr><td>Probe set ID</td><td>Gene Symbol</td><td>Gene Title</td></tr><tr><td>1418368_at</td><td>Retnlb</td><td>resistin like beta</td></tr><tr><td>1422422_at</td><td>Defcr4</td><td>defensin related cryptdin 4</td></tr><tr><td>1425221_at</td><td>Agr3</td><td>anterior gradient homolog 3 (Xenopus laevis)</td></tr><tr><td>1460582_x_at</td><td>a</td><td>Nonagouti</td></tr><tr><td>1421837_at</td><td>Rps18</td><td>ribosomal protein S18</td></tr><tr><td>1422934_x_at</td><td>Defcr-rs7</td><td>defensin related cryptdin, related sequence 7</td></tr><tr><td>452183_a_at</td><td>Gtl2</td><td>GTL2, imprinted maternally expressed untranslated mRNA</td></tr><tr><td>1421838_at</td><td>Rps18</td><td>ribosomal protein S18</td></tr><tr><td>1459443_at</td><td>Kcnq1</td><td>Potassium voltage-gated channel, subfamily Q, member 1</td></tr><tr><td>1447260_at</td><td>ENSMUSG000000734</td><td>ENSMUSG00000073403</td></tr><tr><td>1426340_at</td><td>Slc1a3</td><td>solute carrier family 1 (glial high affinity glutamate transporter), member 3</td></tr><tr><td>1455274_at</td><td>a</td><td>Nonagouti</td></tr><tr><td>1422071_at</td><td>Lgals6</td><td>lectin, galactose binding, soluble 6</td></tr><tr><td>1420748_a_at</td><td>Adat1</td><td>adenosine deaminase, tRNA-specific 1</td></tr><tr><td>1423017_a_at</td><td>Il1rn</td><td>interleukin 1 receptor antagonist</td></tr><tr><td>1449492_a_at</td><td>Lect2</td><td>leukocyte cell-derived chemotaxin 2</td></tr><tr><td>1443536_at</td><td>Slc7a11</td><td>solute carrier family 7 (cationic amino acid transporter, y+ system), member 11</td></tr><tr><td>1446728_at</td><td>D3Ertd797e</td><td>DNA segment, Chr 3, ERATO Doi 797, expressed</td></tr><tr><td>1459779_s_at</td><td>Setd8</td><td>SET domain containing (lysine methyltransferase) 8</td></tr><tr><td>1421257_at</td><td>Pigb</td><td>phosphatidylinositol glycan anchor biosynthesis, class B</td></tr><tr><td>1446730_at</td><td>C79267</td><td>Expressed sequence C79267</td></tr><tr><td>1459834_x_at</td><td>---</td><td>---</td></tr><tr><td>1460604_at</td><td>Cybrd1</td><td>cytochrome b reductase 1</td></tr><tr><td>1427580_a_at</td><td>Rian</td><td>RNA imprinted and accumulated in nucleus</td></tr><tr><td>1418708_at</td><td>Apoc4</td><td>apolipoprotein C-IV</td></tr><tr><td>1422597_at</td><td>Mmp15</td><td>matrix metallopeptidase 15</td></tr><tr><td>1434734_at</td><td>E130016E03Rik</td><td>RIKEN cDNA E130016E03 gene</td></tr><tr><td>1441594_at</td><td>---</td><td>---</td></tr><tr><td>1441624_at</td><td>Sorbs2</td><td>sorbin and SH3 domain containing 2</td></tr><tr><td>1434028_at</td><td>Arnt2</td><td>aryl hydrocarbon receptor nuclear translocator 2</td></tr><tr><td>1427967_at</td><td>Srgap2</td><td>SLIT-ROBO Rho GTPase activating protein 2</td></tr><tr><td>1434497_at</td><td>4933431E20Rik</td><td>RIKEN cDNA 4933431E20 gene</td></tr><tr><td>1444538_at</td><td>Snd1</td><td>Staphylococcal nuclease and tudor domain containing 1</td></tr><tr><td>1457636_x_at</td><td>---</td><td>---</td></tr><tr><td>1436845_at</td><td>Axin2</td><td>axin2</td></tr><tr><td>1457262_at</td><td>2610207I05Rik</td><td>RIKEN cDNA 2610207I05 gene</td></tr><tr><td>1431031_at</td><td>Arid4b</td><td>AT rich interactive domain 4B (Rbp1 like)</td></tr><tr><td>1439380_x_at</td><td>Gtl2</td><td>GTL2, imprinted maternally expressed untranslated mRNA</td></tr><tr><td>1417520_at</td><td>Nfe2l3</td><td>nuclear factor, erythroid derived 2, like 3</td></tr><tr><td>1446376_at</td><td>Rps6kb1</td><td>ribosomal protein S6 kinase, polypeptide 1</td></tr><tr><td>1422882_at</td><td>Sypl</td><td>synaptophysin-like protein</td></tr><tr><td>1444498_at</td><td>---</td><td>---</td></tr><tr><td>1438258_at</td><td>Vldlr</td><td>very low density lipoprotein receptor</td></tr><tr><td>1422954_at</td><td>Zfp60</td><td>zinc finger protein 60</td></tr><tr><td>1425986_a_at</td><td>Dcun1d</td><td>DCUN1D1 DCN1, defective in cullin neddylation 1, domain containing 1 (S. cerevisiae)</td></tr><tr><td>1430458_at</td><td>Supt6h</td><td>suppressor of Ty 6 homolog (S. cerevisiae)</td></tr><tr><td>1434734_at</td><td>E130016E03Rik</td><td>RIKEN cDNA E130016E03 gene</td></tr><tr><td>1435082_at</td><td>Syp1</td><td>synaptophysin-like protein</td></tr><tr><td>1437065_at</td><td>Zbtb20</td><td>zinc finger and BTB domain containing 20</td></tr><tr><td>1441487_at</td><td>Trim2</td><td>tripartite motif protein 2</td></tr><tr><td>1443628_at</td><td>---</td><td>---</td></tr><tr><td>1447386_at</td><td>Usp2</td><td>Ubiquitin specific peptidase 8</td></tr><tr><td>1455327_at</td><td>Senp2</td><td>SUMO/sentrin specific peptidase 2</td></tr></table>	<table><tr><td>Fold Change in Apcfl/fl p53-/- v WT</td></tr><tr><td>0.002</td></tr><tr><td>27.73</td></tr><tr><td>27.20</td></tr><tr><td>17.82</td></tr><tr><td>8.12</td></tr><tr><td>30.91</td></tr><tr><td>25.82</td></tr><tr><td>8.60</td></tr><tr><td>9.67</td></tr><tr><td>12.11</td></tr><tr><td>13.83</td></tr><tr><td>19.31</td></tr><tr><td>11.52</td></tr><tr><td>4.33</td></tr><tr><td>12.54</td></tr><tr><td>43.73</td></tr><tr><td>13.16</td></tr><tr><td>2.39</td></tr><tr><td>6.92</td></tr><tr><td>11.65</td></tr><tr><td>10.65</td></tr><tr><td>4.64</td></tr><tr><td>22.55</td></tr><tr><td>9.54</td></tr><tr><td>19.03</td></tr><tr><td>10.55</td></tr><tr><td>9.11</td></tr><tr><td>5.86</td></tr><tr><td>3.78</td></tr><tr><td>11.43</td></tr><tr><td>9.36</td></tr><tr><td>7.73</td></tr><tr><td>8.68</td></tr><tr><td>5.12</td></tr><tr><td>4.58</td></tr><tr><td>5.35</td></tr><tr><td>3.55</td></tr><tr><td>7.69</td></tr><tr><td>6.40</td></tr><tr><td>5.88</td></tr><tr><td>4.91</td></tr><tr><td>7.23</td></tr><tr><td>6.85</td></tr><tr><td>3.25</td></tr><tr><td>2.49</td></tr><tr><td>3.17</td></tr><tr><td>9.11</td></tr><tr><td>5.30</td></tr><tr><td>12.39</td></tr><tr><td>5.68</td></tr><tr><td>9.06</td></tr><tr><td>2.94</td></tr><tr><td>4.36</td></tr></table>
e952de5166425ac9f132bbdcf30b8ae41e4dd18868ab12534f330e3e2c2e49ef.png	simple	<table><tr><td>Acridine orange</td><td>A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms.</td></tr><tr><td>Acriflavine</td><td>3,6-Diamino-10-methylacridinium chloride mixture. with 3,6-acridinediamine. Fluorescent dye used as a local antiseptic and also as a biological stain. It intercalates into nucleic acids thereby inhibiting bacterial and viral replication.</td></tr><tr><td>Aminacrine</td><td>A highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator.</td></tr><tr><td>Amsacrine</td><td>Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects.</td></tr><tr><td>Ethacridine</td><td>A topically applied anti-infective agent.</td></tr><tr><td>Nitracrine</td><td>Acridine antineoplastic agent used in mammary and ovarian tumors. It inhibits RNA synthesis.</td></tr><tr><td>Proflavine</td><td>3,6-Diaminoacridine. Topical antiseptic used mainly in wound dressings.</td></tr><tr><td>Tacrine</td><td>A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.</td></tr><tr><td>Quinacrine</td><td>An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions as well as a form of contraception/sterilization. It is used in cell biological experiments as an inhibitor of phospholipase A2.</td></tr></table>	<table><tr><td>Acridine orange</td><td>A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms.</td></tr><tr><td>Acriflavine</td><td>3,6-Diamino-10-methylacridinium chloride mixture. with 3,6-acridinediamine. Fluorescent dye used as a local antiseptic and also as a biological stain. It intercalates into nucleic acids thereby inhibiting bacterial and viral replication.</td></tr><tr><td>Aminacrine</td><td>A highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator.</td></tr><tr><td>Amsacrine</td><td>Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects.</td></tr><tr><td>Ethacridine</td><td>A topically applied anti-infective agent.</td></tr><tr><td>Nitracrine</td><td>Acridine antineoplastic agent used in mammary and ovarian tumors. It inhibits RNA synthesis.</td></tr><tr><td>Prof</td><td>3,6-Diaminoacridine. Topical antiseptic used ma</td></tr></table>	<table><tr><td>lavine</td><td>inly in wound dressings.</td></tr><tr><td>Tacrine</td><td>A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.</td></tr><tr><td>Quinacrine</td><td>An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions as well as a form of contraception/sterilization. It is used in cell biological experiments as an inhibitor of phospholipase A2.</td></tr></table>
5f1044d6b74f43c39b13e351f5842198f3e5c14ad8b979ee29a55d2298c59cd0.png	simple	<table><tr><td>Loading of MWCNT (wt%)</td><td>Tg by DMA (°C)</td><td>CTE by TMA (×10<sup>−6</sup> K<sup>−1</sup>)</td></tr><tr><td>Control</td><td>161 ± 0.3</td><td>85 ± 0.3</td></tr><tr><td>0.1 </td><td>160 ± 0.1</td><td>89 ± 0.9</td></tr><tr><td>0.25 </td><td>162 ± 0.3</td><td>90 ± 1.2</td></tr><tr><td>0.4 </td><td>163 ± 0.4</td><td>87 ± 1.4</td></tr><tr><td>0.5 </td><td>163 ± 2.2</td><td>88 ± 0.9</td></tr><tr><td>0.75 </td><td>161 ± 0.9</td><td>87 ± 0.3</td></tr></table>	<table><tr><td>Loading of MWCNT (wt%)</td><td>Tg by DMA (°C)</td><td>CTE by TMA (×10−6 K−1)</td></tr><tr><td>Control</td><td>161 ± 0.3</td><td>85 ± 0.3</td></tr><tr><td>0.1</td><td>160 ± 0.1</td><td>89 ± 0.9</td></tr><tr><td>0.25</td><td>162 ± 0.3</td><td>90 ± 1.2</td></tr><tr><td>0.4</td><td>163 ± 0.4</td><td>87 ± 1.4</td></tr><tr><td></td><td>163 ±</td><td>88 ± 0.</td></tr></table>	<table><tr><td>0.5</td><td> 2.2</td><td>9</td></tr><tr><td>0.75</td><td>161 ± 0.9</td><td>87 ± 0.3</td></tr></table>
d14421206be65684df13611af7db92daa89f4d7c2a825e03031da99a0c2beb07.png	simple	<table><tr><td> </td><td>Drug(s) resistant to</td><td>Typical diseases</td></tr><tr><td>Name of Bacterium</td><td> </td><td> </td></tr><tr><td> <i>Escherichia coli </i> </td><td>Cephalosporins and fluoroquinolones</td><td>Urinary tract infections and blood stream infections </td></tr><tr><td> <i>Klebsiella pneumoniae </i></td><td>Cephalosporins and carbapenems</td><td>Pneumonia, blood stream, and urinary tract infections</td></tr><tr><td> <i>Staphylococcus aureus</i> </td><td>Methicillin</td><td>Wound and blood stream infections</td></tr><tr><td> <i>Streptococcus pneumoniae</i> </td><td>Penicillin</td><td>Pneumonia, meningitis, and otitis</td></tr><tr><td> Nontyphoidal <i>Salmonella</i> </td><td>Fluoroquinolones</td><td>Foodborne diarrhoea, blood stream infections</td></tr><tr><td> <i>Shigella species</i> </td><td>Fluoroquinolones</td><td>Diarrhoea (bacillary dysentery)</td></tr><tr><td> <i>Neisseria gonorrhoeae</i> </td><td>Cephalosporins</td><td>Gonorrhoea</td></tr><tr><td> <i>Mycobacterium tuberculosis </i></td><td>Rifampicin, isoniazid, and fluoroquinolone [4]</td><td>Tuberculosis</td></tr><tr><td>Name of Fungi</td><td> </td><td> </td></tr><tr><td> <i>Candida</i> spp.</td><td>Fluconazole and echinocandins [5]</td><td>Candidiasis</td></tr><tr><td> <i>Cryptococcus neoformans</i></td><td>Fluconazole [17]</td><td>Cryptococcosis</td></tr><tr><td> <i>Aspergillus </i>spp.</td><td>Azoles [18]</td><td>Aspergillosis</td></tr><tr><td> <i>Scopulariopsis </i>spp.</td><td>Amphotericin B, flucytosine, and azoles [19]</td><td>Onychomycosis</td></tr><tr><td>Name of Virus</td><td> </td><td> </td></tr><tr><td> Cytomegalovirus (CMV)</td><td>Ganciclovir and foscarnet [20]</td><td>In AIDS and oncology patients</td></tr><tr><td> Herpes simplex virus (HSV)</td><td>Acyclovir, famciclovir, and valacyclovir [21]</td><td>Herpes simplex</td></tr><tr><td> Human immunodeficiency</td><td> </td><td> </td></tr><tr><td> virus (HIV)</td><td>Antiretroviral drugs [22]</td><td>AIDS</td></tr><tr><td> Influenza virus</td><td>Adamantane derivatives (Amantadine and rimantadine) and neuraminidase inhibitors [23]</td><td>Influenza</td></tr><tr><td> <i>Varicella zoster</i> virus </td><td>Acyclovir and valacyclovir [21]</td><td>Chicken pox</td></tr><tr><td> Hepatitis B virus (HBV)</td><td>Lamivudine [24]</td><td>Hepatitis B</td></tr><tr><td>Name of Parasite</td><td> </td><td> </td></tr><tr><td> <i>Plasmodia</i> spp. </td><td>Chloroquine, artemisinin, and atovaquone [25]</td><td>Malaria</td></tr><tr><td> <i>Leishmania</i> spp.</td><td>Pentavalent antimonials, miltefosine, paromomycin, and amphotericin B [13, 14]</td><td>Leishmaniasis</td></tr><tr><td> Schistosomes </td><td>Praziquantel and oxamniquine [26, 27]</td><td>Schistosomiasis</td></tr><tr><td> <i>Entamoeba</i> </td><td>Metronidazole [28]</td><td>Amoebiasis</td></tr><tr><td> <i>Trichomonas vaginalis</i> </td><td>Nitroimidazoles [29]</td><td>Trichomoniasis</td></tr><tr><td> <i>Toxoplasma gondii </i></td><td>Artemisinin, atovaquone, and sulfadiazine [10–12]</td><td>Toxoplasmosis</td></tr></table>	<table><tr><td></td><td>Drug(s) resistant to</td><td>Typical diseases</td></tr><tr><td>Name of Bacterium</td><td></td><td></td></tr><tr><td>Escherichia coli</td><td>Cephalosporins and fluoroquinolones</td><td>Urinary tract infections and blood stream infections</td></tr><tr><td>Klebsiella pneumoniae</td><td>Cephalosporins and carbapenems</td><td>Pneumonia, blood stream, and urinary tract infections</td></tr><tr><td>Staphylococcus aureus</td><td>Methicillin</td><td>Wound and blood stream infections</td></tr><tr><td>Streptococcus pneumoniae</td><td>Penicillin</td><td>Pneumonia, meningitis, and otitis</td></tr><tr><td>Nontyphoidal Salmonella</td><td>Fluoroquinolones</td><td>Foodborne diarrhoea, blood stream infections</td></tr><tr><td>Shigella species</td><td>Fluoroquinolones</td><td>Diarrhoea (bacillary dysentery)</td></tr><tr><td>Neisseria gonorrhoeae</td><td>Cephalosporins</td><td>Gonorrhoea</td></tr><tr><td>Mycobacterium tuberculosis</td><td>Rifampicin, isoniazid, and fluoroquinolone [4]</td><td>Tuberculosis</td></tr><tr><td>Name of Fungi</td><td></td><td></td></tr><tr><td>Candida spp.</td><td>Fluconazole and echinocandins [5]</td><td>Candidiasis</td></tr><tr><td>Cryptococcus neoformans</td><td>Fluconazole [17]</td><td>Cryptococcosis</td></tr><tr><td>Aspergillus spp.</td><td>Azoles [18]</td><td>Aspergillosis</td></tr><tr><td>Scopulariopsis spp.</td><td>Amphotericin B, flucytosine, and azoles [19]</td><td>Onychomycosis</td></tr><tr><td>Name of Virus</td><td></td><td></td></tr><tr><td>Cytomegalovirus (CMV)</td><td>Ganciclovir and foscarnet [20]</td><td>In AIDS and oncology patients</td></tr><tr><td>Herpes simplex virus (HSV)</td><td>Acyclovir, famciclovir, and valacyclovir [21]</td><td>Herpes simplex</td></tr><tr><td>Human immunodeficiency</td><td></td><td></td></tr><tr><td>virus (HIV)</td><td>Antiretroviral drugs [22]</td><td>AIDS</td></tr><tr><td>Influenza virus</td><td>Adamantane derivatives (Amantadine and rimantadine) and neuraminidase inhibitors [23]</td><td>Influenza</td></tr><tr><td>Varicella zoster virus</td><td>Acyclovir and valacyclovir [21]</td><td>Chicken pox</td></tr><tr><td>Hepatitis B virus (HBV)</td><td>Lamivudine [24]</td><td>Hepatitis B</td></tr></table>	<table><tr><td>Name of Parasite</td><td></td><td></td></tr><tr><td>Plasmodia spp.</td><td>Chloroquine, artemisinin, and atovaquone [25]</td><td>Malaria</td></tr><tr><td>Leishmania spp.</td><td>Pentavalent antimonials, miltefosine, paromomycin, and amphotericin B [13, 14]</td><td>Leishmaniasis</td></tr><tr><td>Schistosomes</td><td>Praziquantel and oxamniquine [26, 27]</td><td>Schistosomiasis</td></tr><tr><td>Entamoeba</td><td>Metronidazole [28]</td><td>Amoebiasis</td></tr><tr><td>Trichomonas vaginalis</td><td>Nitroimidazoles [29]</td><td>Trichomoniasis</td></tr><tr><td>Toxoplasma gondii</td><td>Artemisinin, atovaquone, and sulfadiazine [10–12]</td><td>Toxoplasmosis</td></tr></table>
813222bf4a6f7c538aca063fc60e7114a47efa100e479358e333891134f8a78c.png	simple	<table><tr><td> </td><td>Frequency</td><td>Percentage</td></tr><tr><td>Aetiology</td><td> </td><td> </td></tr><tr><td> Unknown</td><td>294</td><td>66.2%</td></tr><tr><td> Stone</td><td>44</td><td>9.9%</td></tr><tr><td> Nephrotic</td><td>22</td><td>5.0%</td></tr><tr><td> Glomerulonephritis (nephritic)</td><td>22</td><td>5.0%</td></tr><tr><td> Obstructive uropathy</td><td>9</td><td>2.0%</td></tr><tr><td> SSK (small shrunken kidneys)</td><td>28</td><td>6.3%</td></tr><tr><td> Others (Wilms, BOO, gastroenteritis, etc.)</td><td>22</td><td>5.0%</td></tr><tr><td> VUR (vesicoureteral reflux)</td><td>3</td><td>.7%</td></tr><tr><td>Hepatitis B</td><td> </td><td> </td></tr><tr><td> Positive</td><td>11</td><td>2.5%</td></tr><tr><td> Negative</td><td>433</td><td>97.5%</td></tr><tr><td>Hepatitis C</td><td> </td><td> </td></tr><tr><td> Positive</td><td>13</td><td>2.9%</td></tr><tr><td> Negative</td><td>431</td><td>97.1%</td></tr></table>	<table><tr><td></td><td>Frequency</td><td>Percentage</td></tr><tr><td>Aetiology</td><td></td><td></td></tr><tr><td>Unknown</td><td>294</td><td>66.2%</td></tr><tr><td>Stone</td><td>44</td><td>9.9%</td></tr><tr><td>Nephrotic</td><td>22</td><td>5.0%</td></tr><tr><td>Glomerulonephritis (nephritic)</td><td>22</td><td>5.0%</td></tr><tr><td>Obstructive uropathy</td><td>9</td><td>2.0%</td></tr><tr><td>SSK (small shrunken kidneys)</td><td>28</td><td>6.3%</td></tr><tr><td>Others (Wilms, BOO, gastroenteritis, etc.)</td><td>22</td><td>5.0%</td></tr></table>	<table><tr><td></td><td>Frequency</td><td>Percentage</td></tr><tr><td>VUR (vesicoureteral reflux)</td><td>3</td><td>.7%</td></tr><tr><td>Hepatitis B</td><td></td><td></td></tr><tr><td>Positive</td><td>11</td><td>2.5%</td></tr><tr><td>Negative</td><td>433</td><td>97.5%</td></tr><tr><td>Hepatitis C</td><td></td><td></td></tr><tr><td>Positive</td><td>13</td><td>2.9%</td></tr><tr><td>Negative</td><td>431</td><td>97.1%</td></tr></table>
7bf5251b2c367da77d50e300d499b56ce2f8aa8bed7762c2e850e1ded17c4998.png	complex	<table><tr><td>Characteristic</td><td>LN group (n = 14)</td><td><i>P-value</i></td></tr><tr><td>Time since birth of first male child (yr)</td><td></td><td></td></tr><tr><td> 1 to 15 (n = 5)</td><td>9.25 ± 12.37</td><td>NS</td></tr><tr><td> >15 (n = 9)</td><td>5.5 ± 9.6</td><td></td></tr><tr><td>Time since SLE diagnosis (yr)</td><td></td><td></td></tr><tr><td> 1 to 5 (n = 5)</td><td>10 ± 13.6</td><td rowspan="2">NS</td></tr><tr><td> >5 (n = 9)</td><td>5.08 ± 8</td></tr><tr><td>Number of male pregnancies</td><td></td><td></td></tr><tr><td> 1 (n = 0)</td><td>7.99 ± 10.75</td><td rowspan="2">NS</td></tr><tr><td> >1 (n = 4)</td><td>3.7 ± 7.5</td></tr><tr><td>Serum creatinine (mg/dl)</td><td></td><td></td></tr><tr><td> ≤1.5 mg/dl (n = 10)</td><td>9.5 ± 11.2</td><td rowspan="2">0.026</td></tr><tr><td> >1.5 mg/dl (n = 3)</td><td>0.12 ± 0.2</td></tr></table>	<table><tr><td>Characteristic</td><td>LN group (n = 14)</td><td>P-value</td></tr><tr><td>Time since birth of first male child (yr)</td><td></td><td></td></tr><tr><td>1 to 15 (n = 5)</td><td>9.25 ± 12.37</td><td>NS</td></tr><tr><td>>15 </td><td>5.</td><td></td></tr></table>	<table><tr><td>(n = 9)</td><td>5 ± 9.6</td><td></td></tr><tr><td>Time since SLE diagnosis (yr)</td><td></td><td></td></tr><tr><td>1 to 5 (n = 5)</td><td>10 ± 13.6</td><td rowspan="2">NS</td></tr><tr><td>>5 (n = 9)</td><td>5.08 ± 8</td></tr><tr><td>Number of male pregnancies</td><td></td><td></td></tr><tr><td>1 (n = 0)</td><td>7.99 ± 10.75</td><td rowspan="2">NS</td></tr><tr><td>>1 (n = 4)</td><td>3.7 ± 7.5</td></tr><tr><td>Serum creatinine (mg/dl)</td><td></td><td></td></tr><tr><td>≤1.5 mg/dl (n = 10)</td><td>9.5 ± 11.2</td><td rowspan="2">0.026</td></tr><tr><td>>1.5 mg/dl (n = 3)</td><td>0.12 ± 0.2</td></tr></table>